285 results on '"Carlotta Sacerdote"'
Search Results
2. Coffee consumption and risk of endometrial cancer: a pooled analysis of individual participant data in the Epidemiology of Endometrial Cancer Consortium (E2C2)
- Author
-
Marta Crous-Bou, Mengmeng Du, Marc J Gunter, Veronica W Setiawan, Leo J Schouten, Xiao-ou Shu, Nicolas Wentzensen, Kimberly A Bertrand, Linda S Cook, Christine M Friedenreich, Susan M Gapstur, Marc T Goodman, Torukiri I Ibiebele, Carlo La Vecchia, Fabio Levi, Linda M Liao, Eva Negri, Susan E McCann, Kelly O’Connell, Julie R Palmer, Alpa V Patel, Jeanette Ponte, Peggy Reynolds, Carlotta Sacerdote, Rashmi Sinha, Amanda B Spurdle, Britton Trabert, Piet A van den Brandt, Penelope M Webb, Stacey Petruzella, Sara H Olson, Immaculata De Vivo, Epidemiologie, and RS: GROW - R1 - Prevention
- Subjects
Nutrition and Dietetics ,Medicine (miscellaneous) - Abstract
BACKGROUND: Epidemiological studies suggest that coffee consumption may be inversely associated with risk of endometrial cancer (EC), the most common gynecological malignancy in developed countries. Furthermore, coffee consumption may lower circulating levels of estrogen and insulin, hormones implicated in endometrial carcinogenesis. Antioxidants and other chemopreventive compounds in coffee may have anticarcinogenic effects. Based on available meta-analyses, the World Cancer Research Fund concluded that consumption of coffee probably protects against EC.OBJECTIVE: Our main aim was to examine the association between coffee consumption and EC risk by combining individual-level data in a pooled analysis. We also sought to evaluate potential effect modification by other risk factors of EC.PATIENTS AND METHODS: We combined individual-level data from 19 epidemiologic studies (6 cohort, 13 case-control) of 12,159 endometrial cancer cases and 27,479 controls from the Epidemiology of Endometrial Cancer Consortium (E2C2). Logistic regression was used to calculate odds ratios (OR) and their corresponding 95% confidence intervals (CI). All models were adjusted for potential confounders including age, race, body mass index, smoking status, diabetes status, study design and study site.RESULTS: Coffee drinkers had a lower risk of EC compared to non-coffee drinkers (multi-adjusted OR = 0.87, 95% CI = 0.79,0.95). There was a dose-response relationship between higher coffee consumption and lower risk of EC: compared to non-coffee drinkers, the adjusted pooled ORs for those who drank 1, 2-3 and more than 4 cups/day were 0.90 (95% CI = 0.82,1.00), 0.86 (95% CI = 0.78,0.95), and 0.76 (95% CI = 0.66,0.87), respectively (p for trend < 0.001). The inverse association between coffee consumption and EC risk was stronger in participants with body mass index (BMI) over 25 kg/m2.CONCLUSION: The results of the largest analysis to date pooling individual-level data further support the potentially beneficial health effects of coffee consumption in relation to EC, especially among females with higher BMI.
- Published
- 2023
3. Risk prediction models for endometrial cancer: development and validation in an international consortium
- Author
-
Joy Shi, Peter Kraft, Bernard A Rosner, Yolanda Benavente, Amanda Black, Louise A Brinton, Chu Chen, Megan A Clarke, Linda S Cook, Laura Costas, Luigino Dal Maso, Jo L Freudenheim, Jon Frias-Gomez, Christine M Friedenreich, Montserrat Garcia-Closas, Marc T Goodman, Lisa Johnson, Carlo La Vecchia, Fabio Levi, Jolanta Lissowska, Lingeng Lu, Susan E McCann, Kirsten B Moysich, Eva Negri, Kelli O'Connell, Fabio Parazzini, Stacey Petruzella, Jerry Polesel, Jeanette Ponte, Timothy R Rebbeck, Peggy Reynolds, Fulvio Ricceri, Harvey A Risch, Carlotta Sacerdote, Veronica W Setiawan, Xiao-Ou Shu, Amanda B Spurdle, Britton Trabert, Penelope M Webb, Nicolas Wentzensen, Lynne R Wilkens, Wang Hong Xu, Hannah P Yang, Herbert Yu, Mengmeng Du, and Immaculata De Vivo
- Subjects
prediction model ,Cancer Research ,Oncology ,Settore MED/06 - Oncologia Medica ,Settore MED/42 - Igiene Generale e Applicata ,endometrial cancer ,endometrium ,cancer risk ,Settore MED/40 - Ginecologia e Ostetricia ,Settore MED/01 - Statistica Medica - Abstract
Background Endometrial cancer risk stratification may help target interventions, screening, or prophylactic hysterectomy to mitigate the rising burden of this cancer. However, existing prediction models have been developed in select cohorts and have not considered genetic factors. Methods We developed endometrial cancer risk prediction models using data on postmenopausal White women aged 45-85 years from 19 case-control studies in the Epidemiology of Endometrial Cancer Consortium (E2C2). Relative risk estimates for predictors were combined with age-specific endometrial cancer incidence rates and estimates for the underlying risk factor distribution. We externally validated the models in 3 cohorts: Nurses’ Health Study (NHS), NHS II, and the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Results Area under the receiver operating characteristic curves for the epidemiologic model ranged from 0.64 (95% confidence interval [CI] = 0.62 to 0.67) to 0.69 (95% CI = 0.66 to 0.72). Improvements in discrimination from the addition of genetic factors were modest (no change in area under the receiver operating characteristic curves in NHS; PLCO = 0.64 to 0.66). The epidemiologic model was well calibrated in NHS II (overall expected-to-observed ratio [E/O] = 1.09, 95% CI = 0.98 to 1.22) and PLCO (overall E/O = 1.04, 95% CI = 0.95 to 1.13) but poorly calibrated in NHS (overall E/O = 0.55, 95% CI = 0.51 to 0.59). Conclusions Using data from the largest, most heterogeneous study population to date (to our knowledge), prediction models based on epidemiologic factors alone successfully identified women at high risk of endometrial cancer. Genetic factors offered limited improvements in discrimination. Further work is needed to refine this tool for clinical or public health practice and expand these models to multiethnic populations.
- Published
- 2023
4. Risk Factors for Heart Failure Among Pan-European Childhood Cancer Survivors: A PanCareSurFup and ProCardio Cohort and Nested Case-Control Study
- Author
-
Esmée C. de Baat, Elizabeth A.M. Feijen, Raoul C. Reulen, Rodrigue S. Allodji, Francesca Bagnasco, Edit Bardi, Fabiën N. Belle, Julianne Byrne, Elvira C. van Dalen, Ghazi Debiche, Ibrahima Diallo, Desiree Grabow, Lars Hjorth, Momcilo Jankovic, Claudia E. Kuehni, Gill Levitt, Damien Llanas, Jacqueline Loonen, Lorna Z. Zaletel, Milena M. Maule, Lucia Miligi, Helena J.H. van der Pal, Cécile M. Ronckers, Carlotta Sacerdote, Roderick Skinner, Zsuzsanna Jakab, Cristina Veres, Nadia Haddy, David L. Winter, Florent de Vathaire, Michael M. Hawkins, and Leontien C.M. Kremer
- Subjects
Heart Failure ,Cancer Research ,European People ,Antibiotics, Antineoplastic ,360 Soziale Probleme, Sozialdienste ,610 Medicine & health ,Middle Aged ,Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18] ,All institutes and research themes of the Radboud University Medical Center ,Oncology ,Cancer Survivors ,360 Social problems & social services ,Risk Factors ,Neoplasms ,Case-Control Studies ,Humans ,Anthracyclines ,610 Medizin und Gesundheit ,Child - Abstract
PURPOSE Heart failure (HF) is a potentially life-threatening complication of treatment for childhood cancer. We evaluated the risk and risk factors for HF in a large European study of long-term survivors. Little is known of the effects of low doses of treatment, which is needed to improve current treatment protocols and surveillance guidelines. METHODS This study includes the PanCareSurFup and ProCardio cohort of ≥ 5-year childhood cancer survivors diagnosed between 1940 and 2009 in seven European countries (N = 42,361). We calculated the cumulative incidence of HF and conducted a nested case-control study to evaluate detailed treatment-related risk factors. RESULTS The cumulative incidence of HF was 2% (95% CI, 1.7 to 2.2) by age 50 years. The case-control study (n = 1,000) showed that survivors who received a mean heart radiation therapy (RT) dose of 5 to < 15 Gy have an increased risk of HF (odds ratio, 5.5; 95% CI, 2.5 to 12.3), when compared with no heart RT. The risk associated with doses 5 to < 15 Gy increased with exposure of a larger heart volume. In addition, the HF risk increased in a linear fashion with higher mean heart RT doses. Regarding total cumulative anthracycline dose, survivors who received ≥ 100 mg/m2 had a substantially increased risk of HF and survivors treated with a lower dose showed no significantly increased risk of HF. The dose-response relationship appeared quadratic with higher anthracycline doses. CONCLUSION Survivors who received a mean heart RT dose of ≥ 5 Gy have an increased risk of HF. The risk associated with RT increases with larger volumes exposed. Survivors treated with < 100 mg/m2 total cumulative anthracycline dose have no significantly increased risk of HF. These new findings might have consequences for new treatment protocols for children with cancer and for cardiomyopathy surveillance guidelines.
- Published
- 2023
5. Body shape phenotypes of multiple anthropometric traits and cancer risk: a multi-national cohort study
- Author
-
Anja M. Sedlmeier, Vivian Viallon, Pietro Ferrari, Laia Peruchet-Noray, Emma Fontvieille, Amina Amadou, Nazlisadat Seyed Khoei, Andrea Weber, Hansjörg Baurecht, Alicia K. Heath, Kostas Tsilidis, Rudolf Kaaks, Verena Katzke, Elif Inan-Eroglu, Matthias B. Schulze, Kim Overvad, Catalina Bonet, Esther Ubago-Guisado, María-Dolores Chirlaque, Eva Ardanaz, Aurora Perez-Cornago, Valeria Pala, Rosario Tumino, Carlotta Sacerdote, Fabrizio Pasanisi, Kristin B. Borch, Charlotta Rylander, Elisabete Weiderpass, Marc J. Gunter, Béatrice Fervers, Michael F. Leitzmann, Heinz Freisling, [Sedlmeier, Anja M. M.] Univ Regensburg, Dept Epidemiol & Prevent Med, Regensburg, Germany, [Weber, Andrea] Univ Regensburg, Dept Epidemiol & Prevent Med, Regensburg, Germany, [Baurecht, Hansjoerg] Univ Regensburg, Dept Epidemiol & Prevent Med, Regensburg, Germany, [Leitzmann, Michael F. F.] Univ Regensburg, Dept Epidemiol & Prevent Med, Regensburg, Germany, [Viallon, Vivian] Int Agcy Res Canc IARC, Nutr & Metab Branch, Lyon, France, [Ferrari, Pietro] Int Agcy Res Canc IARC, Nutr & Metab Branch, Lyon, France, [Peruchet-Noray, Laia] Int Agcy Res Canc IARC, Nutr & Metab Branch, Lyon, France, [Fontvieille, Emma] Int Agcy Res Canc IARC, Nutr & Metab Branch, Lyon, France, [Weiderpass, Elisabete] Int Agcy Res Canc IARC, Nutr & Metab Branch, Lyon, France, [Gunter, Marc J. J.] Int Agcy Res Canc IARC, Nutr & Metab Branch, Lyon, France, [Freisling, Heinz] Int Agcy Res Canc IARC, Nutr & Metab Branch, Lyon, France, [Peruchet-Noray, Laia] Univ Barcelona, Fac Med, Dept Clin Sci, Barcelona, Spain, [Amadou, Amina] Ctr Leon Berard, Dept Prevent Canc Environm, Lyon, France, [Fervers, Beatrice] Ctr Leon Berard, Dept Prevent Canc Environm, Lyon, France, [Amadou, Amina] INSERM, UMR1296 Radiat Def, Hlth, Environm, Lyon, France, [Fervers, Beatrice] INSERM, UMR1296 Radiat Def, Hlth, Environm, Lyon, France, [Seyed Khoei, Nazlisadat] Univ Vienna, Fac Life Sci, Dept Nutr Sci, Vienna, Austria, [Heath, Alicia K. K.] Imperial Coll London, Sch Publ Hlth, Dept Epidemiol & Biostat, London, England, [Tsilidis, Kostas] Imperial Coll London, Sch Publ Hlth, Dept Epidemiol & Biostat, London, England, [Tsilidis, Kostas] Univ Ioannina, Dept Hyg & Epidemiol, Sch Med, Ioannina, Greece, [Kaaks, Rudolf] German Canc Res Ctr, Div Canc Epidemiol, Heidelberg, Germany, [Katzke, Verena] German Canc Res Ctr, Div Canc Epidemiol, Heidelberg, Germany, [Inan-Eroglu, Elif] German Inst Human Nutr Potsdam Rehbrucke, Dept Mol Epidemiol, Nuthetal, Germany, [Schulze, Matthias B. B.] German Inst Human Nutr Potsdam Rehbrucke, Dept Mol Epidemiol, Nuthetal, Germany, [Overvad, Kim] Aarhus Univ, Dept Publ Hlth, Aarhus, Denmark, [Bonet, Catalina] Catalan Inst Oncol ICO, Unit Nutr & Canc, Barcelona, Spain, [Bonet, Catalina] Bellvitge Biomed Res Inst IDIBELL, Canc Prevent & Palliat Care Program, Nutr & Canc Grp, Epidemiol,Publ Hlth, Barcelona, Spain, [Ubago-Guisado, Esther] Escuela Andaluza Salud Publ EASP, Granada, Spain, [Ubago-Guisado, Esther] Inst Invest Biosanitaria Ibs GRANADA, Granada, Spain, [Ubago-Guisado, Esther] CIBER Epidemiol & Publ Hlth CIBERESP, Madrid, Spain, [Chirlaque, Maria-Dolores] CIBER Epidemiol & Publ Hlth CIBERESP, Madrid, Spain, [Ardanaz, Eva] CIBER Epidemiol & Publ Hlth CIBERESP, Madrid, Spain, [Chirlaque, Maria-Dolores] Reg Hlth Council, Dept Epidemiol, Murcia, Spain, [Chirlaque, Maria-Dolores] Murcia Univ, IMIB Arrixaca, Murcia, Spain, [Ardanaz, Eva] IdiSNA, Navarra Publ Hlth Inst, Pamplona, Spain, [Perez-Cornago, Aurora] Univ Oxford, Nuffield Dept Populat Hlth, Canc Epidemiol Unit, Oxford, England, [Pala, Valeria] Fdn IRCCS Ist Nazl Tumori, Epidemiol & Prevent Unit, Milan, Italy, [Tumino, Rosario] AIRE ONLUS, Hyblean Assoc Epidemiol Res, Ragusa, Italy, [Sacerdote, Carlotta] Citta Salute & Sci Univ Hosp, Unit Canc Epidemiol, Turin, Italy, [Pasanisi, Fabrizio] Feder II Univ Hosp, Dept Clin Med & Surg, Clin Nutr Unit, Naples, Italy, [Borch, Kristin B. B.] UiT Arctic Univ Norway, Fac Hlth Sci, Dept Commun Med, Tromso, Norway, [Rylander, Charlotta] UiT Arctic Univ Norway, Fac Hlth Sci, Dept Commun Med, Tromso, Norway, French National Cancer Institute (l'Institut National du Cancer), International Agency for Research on Cancer (IARC), Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, Danish Cancer Society (Denmark), Ligue Contre le Cancer (France), Institut Gustave Roussy (France), Mutuelle Generale de l'Education Nationale (France), Institut National de la Sante et de la Recherche Medicale (INSERM) (France), German Cancer Aid (Germany), German Cancer Research Center (DKFZ) (Germany), German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE) (Germany), Federal Ministry of Education and Research (BMBF) (Germany), Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy (Italy), Compagnia di San Paolo (Italy), National Research Council (Italy), Dutch Ministry of Public Health, Welfare and Sports (VWS) (The Netherlands), Netherlands Cancer Registry (NKR) (The Netherlands), LK Research Funds (The Netherlands), Dutch Prevention Funds (The Netherlands), Dutch ZON (Zorg Onderzoek Nederland) (The Netherlands), World Cancer Research Fund (WCRF) (The Netherlands), Statistics Netherlands (The Netherlands), Health Research Fund (FIS)-Instituto de Salud Carlos III (ISCIII) (Spain), Regional Government of Andalucia (Spain), Regional Government of Asturias (Spain), Regional Government of Basque Country (Spain), Regional Government of Murcia (Spain), Regional Government of Navarra (Spain), Catalan Institute of Oncology-ICO (Spain), Swedish Cancer Society (Sweden), Swedish Research Council (Sweden), County Council of Skane (Sweden), County Council of Vaesterbotten (Sweden), Cancer Research UK (United Kingdom), and Medical Research Council (United Kingdom)
- Subjects
Cancer Research ,Oncology ,Height ,Fat ,Physical-activity ,Obesity ,Esophageal ,Adenocarcinoma ,Metaanalysis ,Weight ,Nutrition ,Validity - Abstract
Background Classical anthropometric traits may fail to fully represent the relationship of weight, adiposity, and height with cancer risk. We investigated the associations of body shape phenotypes with the risk of overall and site-specific cancers. Methods We derived four distinct body shape phenotypes from principal component (PC) analysis on height, weight, body mass index (BMI), waist (WC) and hip circumferences (HC), and waist-to-hip ratio (WHR). The study included 340,152 men and women from 9 European countries, aged mostly 35–65 years at recruitment (1990–2000) in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Cox proportional hazards regression was used to estimate multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). Results After a median follow-up of 15.3 years, 47,110 incident cancer cases were recorded. PC1 (overall adiposity) was positively associated with the risk of overall cancer, with a HR per 1 standard deviation (SD) increment equal to 1.07 (95% confidence interval 1.05 to 1.08). Positive associations were observed with 10 cancer types, with HRs (per 1 SD) ranging from 1.36 (1.30–1.42) for endometrial cancer to 1.08 (1.03–1.13) for rectal cancer. PC2 (tall stature with low WHR) was positively associated with the risk of overall cancer (1.03; 1.02–1.04) and five cancer types which were not associated with PC1. PC3 (tall stature with high WHR) was positively associated with the risk of overall cancer (1.04; 1.03–1.05) and 12 cancer types. PC4 (high BMI and weight with low WC and HC) was not associated with overall risk of cancer (1.00; 0.99–1.01). Conclusions In this multi-national study, distinct body shape phenotypes were positively associated with the incidence of 17 different cancers and overall cancer.
- Published
- 2022
6. Protein and amino acid intakes in relation to prostate cancer risk and mortality—A prospective study in the European Prospective Investigation into Cancer and Nutrition
- Author
-
Julie A. Schmidt, Inge Huybrechts, Kim Overvad, Anne Kirstine Eriksen, Anne Tjønneland, Rudolf Kaaks, Verena Katzke, Matthias B. Schulze, Valeria Pala, Carlotta Sacerdote, Rosario Tumino, Bas Bueno‐de‐Mesquita, Maria‐Jose Sánchez, José M. Huerta, Aurelio Barricarte, Pilar Amiano, Antonio Agudo, Anders Bjartell, Tanja Stocks, Elin Thysell, Maria Wennberg, Elisabete Weiderpass, Ruth C. Travis, Timothy J. Key, and Aurora Perez‐Cornago
- Subjects
Male ,Cancer Research ,CROSS-SECTIONAL ANALYSIS ,EGG INTAKE ,dietary protein intakes ,Risk Factors ,GROWTH-FACTOR-I ,Humans ,DIETARY QUESTIONNAIRES ,Radiology, Nuclear Medicine and imaging ,Prospective Studies ,Amino Acids ,ONE-CARBON METABOLISM ,METAANALYSIS ,Cancer och onkologi ,prostate cancer mortality ,MEAT-EATERS ,Prostatic Neoplasms ,ASSOCIATION ,dietary amino acid intakes ,Diet ,IGF-I ,Oncology ,prostate cancer incidence ,Cancer and Oncology ,tumour subtypes ,RESTRICTION - Abstract
BACKGROUND: The association between protein intake and prostate cancer risk remains unclear.AIMS: To prospectively investigate the associations of dietary intakes of total protein, protein from different dietary sources, and amino acids with prostate cancer risk and mortality.METHODS: In 131,425 men from the European Prospective Investigation into Cancer and Nutrition, protein and amino acid intakes were estimated using validated dietary questionnaires. Multivariable-adjusted Cox regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).RESULTS: During a mean follow-up of 14.2 years, 6939 men were diagnosed with prostate cancer and 914 died of the disease. Dairy protein was positively associated with overall prostate cancer risk in the three highest fifths compared to the lowest (HR Q3 =1.14 (95% CI 1.05-1.23); HR Q 4=1.09 (1.01-1.18); HR Q5 =1.10 (1.02-1.19)); similar results were observed for yogurt protein (HR Q3 =1.14 (1.05-1.24); HR Q4 =1.09 (1.01-1.18); HR Q5 =1.12 (1.04-1.21)). For egg protein intake and prostate cancer mortality, no association was observed by fifths, but there was suggestive evidence of a positive association in the analysis per standard deviation increment. There was no strong evidence of associations with different tumour subtypes. DISCUSSION: Considering the weak associations and many tests, the results must be interpreted with caution.CONCLUSION: This study does not provide strong evidence for an association of intakes of total protein, protein from different dietary sources or amino acids with prostate cancer risk or mortality. However, our results may suggest some weak positive associations, which need to be confirmed in large-scale, pooled analyses of prospective data.
- Published
- 2022
7. Baseline and lifetime alcohol consumption and risk of skin cancer in the European Prospective Investigation into Cancer and Nutrition cohort ( <scp>EPIC</scp> )
- Author
-
Yahya Mahamat‐Saleh, Marie Al‐Rahmoun, Gianluca Severi, Reza Ghiasvand, Marit B. Veierod, Saverio Caini, Domenico Palli, Edoardo Botteri, Carlotta Sacerdote, Fulvio Ricceri, Marko Lukic, Maria J. Sánchez, Valeria Pala, Rosario Tumino, Paolo Chiodini, Pilar Amiano, Sandra Colorado‐Yohar, María‐Dolores Chirlaque, Eva Ardanaz, Catalina Bonet, Verena Katzke, Rudolf Kaaks, Matthias B. Schulze, Kim Overvad, Christina C. Dahm, Christian S. Antoniussen, Anne Tjønneland, Cecilie Kyrø, Bas Bueno‐de‐Mesquita, Jonas Manjer, Malin Jansson, Anders Esberg, Nagisa Mori, Pietro Ferrari, Elisabete Weiderpass, Marie‐Christine Boutron‐Ruault, Marina Kvaskoff, Mahamat-Saleh, Yahya, Al-Rahmoun, Marie, Severi, Gianluca, Ghiasvand, Reza, Veierod, Marit B, Caini, Saverio, Palli, Domenico, Botteri, Edoardo, Sacerdote, Carlotta, Ricceri, Fulvio, Lukic, Marko, Sánchez, Maria J, Pala, Valeria, Tumino, Rosario, Chiodini, Paolo, Amiano, Pilar, Colorado-Yohar, Sandra, Chirlaque, María-Dolore, Ardanaz, Eva, Bonet, Catalina, Katzke, Verena, Kaaks, Rudolf, Schulze, Matthias B, Overvad, Kim, Dahm, Christina C, Antoniussen, Christian S, Tjønneland, Anne, Kyrø, Cecilie, Bueno-de-Mesquita, Ba, Manjer, Jona, Jansson, Malin, Esberg, Ander, Mori, Nagisa, Ferrari, Pietro, Weiderpass, Elisabete, Boutron-Ruault, Marie-Christine, and Kvaskoff, Marina
- Subjects
Male ,Cancer och onkologi ,Cancer Research ,Skin Neoplasms ,Alcohol Drinking ,alcohol ,keratinocyte cancers ,Public Health, Global Health, Social Medicine and Epidemiology ,Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi ,cutaneous melanoma ,cohort studies ,Oncology ,Carcinoma, Basal Cell ,Risk Factors ,Cancer and Oncology ,Carcinoma, Squamous Cell ,epidemiology ,Humans ,Female ,Prospective Studies ,Melanoma ,cohort studie - Abstract
Experimental evidence suggests that alcohol induces cutaneous carcinogenesis, yet epidemiological studies on the link between alcohol intake and skin cancer have been inconsistent. The European Prospective Investigation into Cancer and Nutrition (EPIC) is a prospective cohort initiated in 1992 in 10 European countries. Alcohol intake at baseline and average lifetime alcohol intake were assessed using validated country-specific dietary and lifestyle questionnaires. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated in Cox models. A total of 14 037 skin cancer cases (melanoma: n = 2457; basal-cell carcinoma (BCC): n = 8711; squamous-cell carcinoma (SCC): n = 1928; unknown: n = 941) were identified among 450 112 participants (average follow-up: 15 years). Baseline alcohol intake was positively associated with SCC (>15 vs 0.1-4.9 g/day: HR = 1.44, 95% CI = 1.17-1.77; Ptrend = .001), BCC (HR = 1.12, 95% CI = 1.01-1.23; Ptrend = .04), and melanoma risks in men (HR = 1.17, 95% CI = 0.95-1.44; Ptrend = .17), while associations were more modest in women (SCC: HR = 1.09, 95% CI = 0.90-1.30; Ptrend = .13; BCC: HR = 1.08, 95% CI = 1.00-1.17,Ptrend = .03; melanoma: HR = 0.93, 95% CI = 0.80-1.08, Ptrend = .13). Associations were similar for lifetime alcohol intake, with an attenuated linear trend. Lifetime liquor/spirit intake was positively associated with melanoma (fourth vs first quartile: HR = 1.47, 95% CI = 1.08-1.99; Ptrend = .0009) and BCC risks in men (HR = 1.17, 95% CI = 1.04-1.31;Ptrend = .14). Baseline and lifetime intakes of wine were associated with BCC risk (HR = 1.25 in men; HR = 1.11-1.12; in women). No statistically significant associations were found between beverage types and SCC risk. Intake of beer was not associated with skin cancer risk. Our study suggests positive relationships between alcohol intake and skin cancer risk, which may have important implications for the primary prevention of skin cancer. What's new? Drinking alcohol can make the skin more sensitive to sunlight and vulnerable to skin cancer. Here, the authors conducted a large prospective cohort study to evaluate whether alcohol consumption correlates with skin cancer risk. Among the 450 112 participants, there were 2457 cases of melanoma, 8711 of basal cell carcinoma, and 1928 of squamous cell carcinoma. There was a positive association between alcohol and all three cancer types, stronger in men than in women. The association varied somewhat by beverage type.
- Published
- 2022
8. Risk Factors for Primary Bone Cancer After Childhood Cancer: A PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies Nested Case-Control Study
- Author
-
Raoul C. Reulen, David L. Winter, Ibrahim Diallo, Cristina Veres, Damien Llanas, Rodrigue S. Allodji, Francesca Bagnasco, Edit Bárdi, Elizabeth A.M. Feijen, Daniela Alessi, Miranda M. Fidler-Benaoudia, Stine Høgsholt, Jop C. Teepen, Helena Linge, Nadia Haddy, Julianne Byrne, Ghazi Debiche, Desiree Grabow, Thorgerdur Gudmundsdottir, Romain Fauchery, Wael Zrafi, Gisela Michel, Hilde Øfstaas, Peter Kaatsch, Giao Vu-Bezin, Helen Jenkinson, Melanie Kaiser, Roderick Skinner, Trevor Cole, Nicolas Waespe, Grit Sommer, Susanne Nordenfelt, Momcilo Jankovic, Tuomas Lähteenmäki Taalas, Milena M. Maule, Helena J.H. van der Pal, Cécile M. Ronckers, Flora E. van Leeuwen, Judith L. Kok, Monica Terenziani, Maria Winther Gunnes, Thomas Wiebe, Carlotta Sacerdote, Zsuzsanna Jakab, Riccardo Haupt, Päivi M. Lähteenmäki, Lorna Zadravec Zaletel, Claudia E. Kuehni, Jeanette Falck Winther, Leontien C.M. Kremer, Lars Hjorth, Florent de Vathaire, and Michael M. Hawkins
- Subjects
Cancer Research ,Oncology - Abstract
PURPOSE Radiation to the bone and exposure to alkylating agents increases the risk of bone cancer among survivors of childhood cancer, but there is uncertainty regarding the risks of bone tissue radiation doses below 10 Gy and the dose-response relationship for specific types of chemotherapy. METHODS Twelve European countries contributed 228 cases and 228 matched controls to a nested case-control study within a cohort of 69,460 5-year survivors of childhood cancer. Odds ratios (ORs) of developing bone cancer for different levels of cumulative radiation exposure and cumulative doses of specific types of chemotherapy were calculated. Excess ORs were calculated to investigate the shape and extent of any dose-response relationship. RESULTS The OR associated with bone tissue exposed to 1-4 Gy was 4.8-fold (95% CI, 1.2 to 19.6) and to 5-9 Gy was 9.6-fold (95% CI, 2.4 to 37.4) compared with unexposed bone tissue. The OR increased linearly with increasing dose of radiation ( Ptrend < .001) up to 78-fold (95% CI, 9.2 to 669.9) for doses of ≥40 Gy. For cumulative alkylating agent doses of 10,000-19,999 and ≥20,000 mg/m2, the radiation-adjusted ORs were 7.1 (95% CI, 2.2 to 22.8) and 8.3 (95% CI, 2.8 to 24.4), respectively, with independent contributions from each of procarbazine, ifosfamide, and cyclophosphamide. Other cytotoxics were not associated with bone cancer. CONCLUSION To our knowledge, we demonstrate—for the first time—that the risk of bone cancer is increased 5- to 10-fold after exposure of bone tissue to cumulative radiation doses of 1-9 Gy. Alkylating agents exceeding 10,000 mg/m2 increase the risk 7- to 8-fold, particularly following procarbazine, ifosfamide, and cyclophosphamide. These substantially elevated risks should be used to develop/update clinical follow-up guidelines and survivorship care plans.
- Published
- 2023
9. Supplementary Tables 1-6 from Circulating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort
- Author
-
Renée T. Fortner, Rudolf Kaaks, Elio Riboli, Melissa Merritt, Sabina Rinaldi, Mark Gunter, Laure Dossus, Ruth Travis, Kay Tee Khaw, Pilar Amiano, Eva Ardanaz, Maria-Dolores Chirlaque, Maria-José Sánchez, Antonio Agudo, Elisabete Weiderpass, Petra H. Peeters, Carla H. van Gils, H.B(as). Bueno-de-Mesquita, Carlotta Sacerdote, Rosario Tumino, Amalia Mattiello, Valeria Pala, Domenico Palli, Antonia Trichopoulou, Eleni-Maria Papatesta, Pagona Lagiou, Heiner Boeing, Marina Kvaskoff, Mathilde His, Marie-Christine Boutron-Ruault, Anne Tjønneland, Marianne Holm, Kim Overvad, Theron Johnson, Helena Schock, and Danja Sarink
- Abstract
Supplementary table 1. Correlations of sRANKL and the sRANKL/OPG ratio with select hormones among controls: EPIC cohort nested case-control study. Supplementary table 2. Distribution of covariates by quintiles of sRANKL. Supplementary table 3. Circulating concentrations of sRANKL and breast cancer risk by hormone-receptor subtype and menopausal status at blood collection. Supplementary table 4. The sRANKL/OPG ratio and breast cancer risk by hormone-receptor subtype and menopausal status at blood collection. Supplementary table 5. sRANKL additionally adjusted for continuous (log2) OPG and breast cancer risk by hormone-receptor subtype: EPIC nested case-control study. Supplementary table 6. sRANKL/OPG cross-classification based on median split of sRANKL and OPG and breast cancer risk by hormone-receptor subtype: EPIC nested case-control study.
- Published
- 2023
10. Supplementary Figure 1 from Postmenopausal Serum Sex Steroids and Risk of Hormone Receptor–Positive and -Negative Breast Cancer: a Nested Case–Control Study
- Author
-
Rudolf Kaaks, Elio Riboli, David Cox, Afshan Siddiq, Isabelle Romieu, Naomi E. Allen, Timothy J. Key, Nick Wareham, Kay-Tee Khaw, Petra H. Peeters, Carla H. van Gils, Martine M. Ros, Bas Bueno-de-Mesquita, Eva Ardanaz, Pilar Amiano, Maria-José Sánchez, Genevieve Buckland, Laudina Rodríguez, Carlotta Sacerdote, Rosario Tumino, Salvatore Panico, Vittorio Krogh, Domenico Palli, Dimitrios Trichopoulos, Pagona Lagiou, Antonia Trichopoulou, Madlen Schütze, Heiner Boeing, Alina Vrieling, Jenny Chang-Claude, Françoise Clavel-Chapelon, Pierre Engel, Sylvie Mesrine, Kim Overvad, Anja Olsen, Anne Tjønneland, Sabina Rinaldi, Susen Becker, Laure Dossus, Annekatrin Lukanova, and Rebecca E. James
- Abstract
PDF file - 551K
- Published
- 2023
11. Perspective on This Article from Anthropometric Measures, Physical Activity, and Risk of Glioma and Meningioma in a Large Prospective Cohort Study
- Author
-
Elio Riboli, Paolo Vineis, Isabelle Romieu, Ruth C. Travis, Naomi E. Allen, Nick Wareham, Kay-Tee Khaw, Signe Borgquist, Jonas Manjer, Beatrice S. Melin, Göran Hallmans, Eric J. Duell, Laudina Rodríguez, Maria José Sánchez, Miren Dorronsoro, Maria-Dolores Chirlaque, Aurelio Barricarte, Anne M. May, Petra H. M. Peeters, H. Bas Bueno-de-Mesquita, Amalia Mattiello, Rosario Tumino, Domenico Palli, Claudia Agnoli, Carlotta Sacerdote, Andreas Kyrozis, Christina Bamia, Antonia Trichopoulou, Annika Steffen, Heiner Boeing, Brigit Teucher, Christina C. Dahm, Kim Overvad, Anja Olsen, Anne Tjønneland, Brigitte Schlehofer, Valentina Gallo, Gerald Bové, and Dominique S. Michaud
- Abstract
Perspective on This Article from Anthropometric Measures, Physical Activity, and Risk of Glioma and Meningioma in a Large Prospective Cohort Study
- Published
- 2023
12. Data from Postmenopausal Serum Sex Steroids and Risk of Hormone Receptor–Positive and -Negative Breast Cancer: a Nested Case–Control Study
- Author
-
Rudolf Kaaks, Elio Riboli, David Cox, Afshan Siddiq, Isabelle Romieu, Naomi E. Allen, Timothy J. Key, Nick Wareham, Kay-Tee Khaw, Petra H. Peeters, Carla H. van Gils, Martine M. Ros, Bas Bueno-de-Mesquita, Eva Ardanaz, Pilar Amiano, Maria-José Sánchez, Genevieve Buckland, Laudina Rodríguez, Carlotta Sacerdote, Rosario Tumino, Salvatore Panico, Vittorio Krogh, Domenico Palli, Dimitrios Trichopoulos, Pagona Lagiou, Antonia Trichopoulou, Madlen Schütze, Heiner Boeing, Alina Vrieling, Jenny Chang-Claude, Françoise Clavel-Chapelon, Pierre Engel, Sylvie Mesrine, Kim Overvad, Anja Olsen, Anne Tjønneland, Sabina Rinaldi, Susen Becker, Laure Dossus, Annekatrin Lukanova, and Rebecca E. James
- Abstract
Prediagnostic endogenous sex steroid hormone levels have well established associations with overall risk of breast cancer. While evidence toward the existence of distinct subtypes of breast cancer accumulates, few studies have investigated the associations of sex steroid hormone levels with risk of hormone receptor [estrogen receptor (ER) and/or progesterone receptor (PR)] defined breast cancer. In a case–control study nested within the EPIC cohort (European Prospective Investigation into Cancer and Nutrition), estradiol, testosterone, and sex hormone–binding globulin levels were measured in prediagnostic serum samples from postmenopausal women not using hormone replacement therapy at blood donation. A total of 554 women who developed invasive breast cancer with information on receptor status were matched with 821 control subjects. Conditional logistic regression models estimated breast cancer risk with hormone concentrations according to hormone receptor status of the tumor. Sex steroid hormones were associated with risks of not only ER+PR+ breast cancer [estradiol OR for highest vs. lowest tertile = 2.91 (95% CI: 1.62–5.23), Ptrend = 0.002; testosterone OR = 2.27 (95% CI: 1.35–3.81), Ptrend = 0.002] but also of ER-PR- breast cancer [estradiol OR = 2.11 (95% CI: 1.00–4.46), Ptrend = 0.05; testosterone OR = 2.06 (95% CI: 0.95–4.46), Ptrend = 0.03], with associations appearing somewhat stronger in the receptor-positive disease. Serum androgens and estrogens are associated with risks of both hormone receptor–negative as well as receptor–positive breast tumors. Further research is needed to establish through which molecular pathways, and during which evolutionary stages of development, androgens and estrogens can promote the occurrence of both receptor-positive and -negative clinical breast tumors. Cancer Prev Res; 4(10); 1626–35. ©2011 AACR.
- Published
- 2023
13. Supplementary Figure Legend from Postmenopausal Serum Sex Steroids and Risk of Hormone Receptor–Positive and -Negative Breast Cancer: a Nested Case–Control Study
- Author
-
Rudolf Kaaks, Elio Riboli, David Cox, Afshan Siddiq, Isabelle Romieu, Naomi E. Allen, Timothy J. Key, Nick Wareham, Kay-Tee Khaw, Petra H. Peeters, Carla H. van Gils, Martine M. Ros, Bas Bueno-de-Mesquita, Eva Ardanaz, Pilar Amiano, Maria-José Sánchez, Genevieve Buckland, Laudina Rodríguez, Carlotta Sacerdote, Rosario Tumino, Salvatore Panico, Vittorio Krogh, Domenico Palli, Dimitrios Trichopoulos, Pagona Lagiou, Antonia Trichopoulou, Madlen Schütze, Heiner Boeing, Alina Vrieling, Jenny Chang-Claude, Françoise Clavel-Chapelon, Pierre Engel, Sylvie Mesrine, Kim Overvad, Anja Olsen, Anne Tjønneland, Sabina Rinaldi, Susen Becker, Laure Dossus, Annekatrin Lukanova, and Rebecca E. James
- Abstract
PDF file - 54K
- Published
- 2023
14. Data from Investigation of Dietary Factors and Endometrial Cancer Risk Using a Nutrient-wide Association Study Approach in the EPIC and Nurses' Health Study (NHS) and NHSII
- Author
-
Marc J. Gunter, Elio Riboli, Chirag J. Patel, Isabelle Romieu, Sabina Rinaldi, Ruth C. Travis, Nicholas Wareham, Kay-Tee Khaw, Annika Idahl, Lena Maria Nilsson, Emily Sonestedt, Ulrica Ericson, Saioa Chamosa, Aurelio Barricarte, D. Salmerón, María-José Sánchez, Eric J. Duell, J. Ramón Quirós, Guri Skeie, Inger T. Gram, Petra H. Peeters, N. Charlotte Onland-Moret, H.B(as). Bueno-de-Mesquita, Amalia Mattiello, Carlotta Sacerdote, Rosario Tumino, Sara Grioni, Domenico Palli, Dimitrios Trichopoulos, Christina Bamia, Antonia Trichopoulou, Heiner Boeing, Krasimira Aleksandrova, Rudolf Kaaks, Renée T. Fortner, Guy Fagherazzi, Marie-Christine Boutron-Ruault, Laure Dossus, Kim Overvad, Christina C. Dahm, Kristina E.N. Petersen, Anne Tjønneland, Elisabete Weiderpass, Konstantinos K. Tsilidis, Judy Fernandes, Susan E. Hankinson, Immaculata De Vivo, Shelley S. Tworoger, Ioanna Tzoulaki, and Melissa A. Merritt
- Abstract
Data on the role of dietary factors in endometrial cancer development are limited and inconsistent. We applied a “nutrient-wide association study” approach to systematically evaluate dietary risk associations for endometrial cancer while controlling for multiple hypothesis tests using the false discovery rate (FDR) and validating the results in an independent cohort. We evaluated endometrial cancer risk associations for dietary intake of 84 foods and nutrients based on dietary questionnaires in three prospective studies, the European Prospective Investigation into Cancer and Nutrition (EPIC; N = 1,303 cases) followed by validation of nine foods/nutrients (FDR ≤ 0.10) in the Nurses' Health Studies (NHS/NHSII; N = 1,531 cases). Cox regression models were used to estimate HRs and 95% confidence intervals (CI). In multivariate adjusted comparisons of the extreme categories of intake at baseline, coffee was inversely associated with endometrial cancer risk (EPIC, median intake 750 g/day vs. 8.6; HR, 0.81; 95% CI, 0.68–0.97, Ptrend = 0.09; NHS/NHSII, median intake 1067 g/day vs. none; HR, 0.82; 95% CI, 0.70–0.96, Ptrend = 0.04). Eight other dietary factors that were associated with endometrial cancer risk in the EPIC study (total fat, monounsaturated fat, carbohydrates, phosphorus, butter, yogurt, cheese, and potatoes) were not confirmed in the NHS/NHSII. Our findings suggest that coffee intake may be inversely associated with endometrial cancer risk. Further data are needed to confirm these findings and to examine the mechanisms linking coffee intake to endometrial cancer risk to develop improved prevention strategies. Cancer Epidemiol Biomarkers Prev; 24(2); 466–71. ©2015 AACR.
- Published
- 2023
15. Data from Prolactin Determinants in Healthy Women: A Large Cross-Sectional Study within the EPIC Cohort
- Author
-
Rudolf Kaaks, Elio Riboli, Marc J. Gunter, Ruth C. Travis, Timothy J. Key, Kay-Tee Khaw, Marit Waaseth, Eiliv Lund, Elisabete Weiderpass, Eva Lundin, Annika Idahl, N. Charlotte Onland-Moret, Evelyn M. Monninkhof, H. Bas Bueno-de-Mesquita, Aurelio Barricarte, José María Huerta Castaño, Pilar Amiano, Esther Molina-Montes, Soledad Sánchez, Genevieve Buckland, Amalia Mattiello, Carlotta Sacerdote, Rosario Tumino, Claudia Agnoli, Giovanna Masala, Dimitrios Trichopoulos, Pagona Lagiou, Antonia Trichopoulou, Heiner Boeing, Isabelle Romieu, Sabina Rinaldi, Laura Baglietto, Kim Overvad, Anja Olsen, Anne Tjønneland, Françoise Clavel-Chapelon, Laure Dossus, Theron Johnson, Disorn Sookthai, and Kaja Tikk
- Abstract
Background: Experimental and epidemiologic data suggest that higher circulating prolactin is associated with breast cancer risk; however, how various risk factors for breast cancer influence prolactin levels in healthy women is not clear.Methods: We analyzed cross-sectional associations between several suggested reproductive and lifestyle risk factors for breast cancer and circulating prolactin among pre- and postmenopausal women, taking into account the use of current postmenopausal hormone therapy, among 2,560 controls from a breast cancer nested case–control study within the EPIC cohort.Results: Adjusted geometric mean prolactin levels were significantly higher among premenopausal women, and among postmenopausal women using hormone therapy compared with nonusers (8.2, 7.0, and 6.3 ng/mL, respectively; Pcat = Pcat = 0.001). Prolactin levels were lower among parous women compared with nulliparous women (8.61 vs. 10.95 ng/mL; Pcat = 0.0002, premenopausal women); the magnitude of this difference depended on the number of full-term pregnancies (22.1% lower, ≥3 vs. 1 pregnancy, Ptrend = 0.01). Results for parity were similar but lower in magnitude among postmenopausal women. Prolactin did not vary by other studied factors, with the exception of lower levels among postmenopausal smokers compared with never smokers.Conclusions: Our study shows that current hormone therapy use, especially the use of combined hormone therapy, is associated with higher circulating prolactin levels in postmenopausal women, and confirms prior findings of lower circulating prolactin in parous women.Impact: Our study extends the knowledge linking various breast cancer risk factors with circulating prolactin. Cancer Epidemiol Biomarkers Prev; 23(11); 2532–42. ©2014 AACR.
- Published
- 2023
16. Supplementary Table S2 from Shorter Leukocyte Telomere Length Is Independently Associated with Poor Survival in Patients with Bladder Cancer
- Author
-
Giuseppe Matullo, Carlotta Sacerdote, Paolo Vineis, Bruno Frea, Dario Fontana, Andrea Zitella, Luigi Rolle, Paolo Gontero, Paolo Destefanis, Giuseppina Cucchiarale, Giovanni Casetta, Andrea Bosio, Rossana Critelli, Alessandra Allione, Clara Viberti, Barbara Pardini, Giovanni Fiorito, Simonetta Guarrera, Federica Modica, and Alessia Russo
- Abstract
Supplementary Table S2. TL quartiles and OS association analysis (Crude Cox regression).
- Published
- 2023
17. Supplementary Figure S1 from Shorter Leukocyte Telomere Length Is Independently Associated with Poor Survival in Patients with Bladder Cancer
- Author
-
Giuseppe Matullo, Carlotta Sacerdote, Paolo Vineis, Bruno Frea, Dario Fontana, Andrea Zitella, Luigi Rolle, Paolo Gontero, Paolo Destefanis, Giuseppina Cucchiarale, Giovanni Casetta, Andrea Bosio, Rossana Critelli, Alessandra Allione, Clara Viberti, Barbara Pardini, Giovanni Fiorito, Simonetta Guarrera, Federica Modica, and Alessia Russo
- Abstract
Supplementary Figure S1. Kaplan-Meier OS curves of bladder cancer patients stratified for TL quartiles. OS, overall survival; TL, telomere length.
- Published
- 2023
18. Data from Prospective Identification of Elevated Circulating CDCP1 in Patients Years before Onset of Lung Cancer
- Author
-
Marc Chadeau-Hyam, Roel C.H. Vermeulen, Torkjel M. Sandanger, Mattias Johansson, Paolo Vineis, Augustin Scalbert, Pekka Keski-Rahkonen, Mikael Johansson, Matthias B. Schulze, Rosario Tumino, Salvatore Panico, Carlotta Sacerdote, Domenico Palli, Claudia Agnoli, Therese Haugdahl Nøst, Matthew D. Whitaker, Dusan Petrovic, Karl Smith-Byrne, Florence Guida, Barbara Bodinier, and Sonia Dagnino
- Abstract
Increasing evidence points to a role for inflammation in lung carcinogenesis. A small number of circulating inflammatory proteins have been identified as showing elevated levels prior to lung cancer diagnosis, indicating the potential for prospective circulating protein concentration as a marker of early carcinogenesis. To identify novel markers of lung cancer risk, we measured a panel of 92 circulating inflammatory proteins in 648 prediagnostic blood samples from two prospective cohorts in Italy and Norway (women only). To preserve the comparability of results and protect against confounding factors, the main statistical analyses were conducted in women from both studies, with replication sought in men (Italian participants). Univariate and penalized regression models revealed for the first time higher blood levels of CDCP1 protein in cases that went on to develop lung cancer compared with controls, irrespective of time to diagnosis, smoking habits, and gender. This association was validated in an additional 450 samples. Associations were stronger for future cases of adenocarcinoma where CDCP1 showed better explanatory performance. Integrative analyses combining gene expression and protein levels of CDCP1 measured in the same individuals suggested a link between CDCP1 and the expression of transcripts of LRRN3 and SEM1. Enrichment analyses indicated a potential role for CDCP1 in pathways related to cell adhesion and mobility, such as the WNT/β-catenin pathway. Overall, this study identifies lung cancer–related dysregulation of CDCP1 expression years before diagnosis.Significance:Prospective proteomics analyses reveal an association between increased levels of circulating CDCP1 and lung carcinogenesis irrespective of smoking and years before diagnosis, and integrating gene expression indicates potential underlying mechanisms.See related commentary by Itzstein et al., p. 3441.
- Published
- 2023
19. Supplemental tables 1 and 2 from Inflammatory Markers and Risk of Epithelial Ovarian Cancer by Tumor Subtypes: The EPIC Cohort
- Author
-
Renée T. Fortner, Rudolf Kaaks, Elio Riboli, Marc J. Gunter, Melissa A. Merritt, Isabelle Romieu, Sabina Rinaldi, Kay-Tee Khaw, Ruth C. Travis, Annika Idahl, Eva Lundin, Jenny Brändstedt, Eva Ardanaz, José María Huerta Castaño, Nerea Larrañaga, Maria-José Sànchez-Pérez, Mireia Obon-Santacana, Soledad Sánchez, Inger T. Gram, Elisabete Weiderpass, N. Charlotte Onland-Moret, Petra H. M. Peeters, H. B(as). Bueno-de-Mesquita, Amalia Mattiello, Carlotta Sacerdote, Rosario Tumino, Giovanna Tagliabue, Giovanna Masala, Pagona Lagiou, Vassiliki Benetou, Antonia Trichopolou, Heiner Boeing, Laura Baglietto, Françoise Clavel-Chapelon, Laure Dossus, Kim Overvad, Louise Hansen, Anne Tjønneland, Helena Schock, and Jennifer Ose
- Abstract
Supplemental tables 1 and 2. Supplementary Table 1. Odds ratios (95% CI) for ovarian cancer by tertile concentrations and for doubling in CRP and IL-6 by menopausal status, age at diagnosis and HRT use at blood donation. Supplementary Table 2. Odds ratios (95% CI) for ovarian cancer for doubling in CRP and IL-6 by BMI categories and waist circumference, mutual adjusted for IL-6 and CRP.
- Published
- 2023
20. Supplementary Tables S1-S3 from Prolactin Determinants in Healthy Women: A Large Cross-Sectional Study within the EPIC Cohort
- Author
-
Rudolf Kaaks, Elio Riboli, Marc J. Gunter, Ruth C. Travis, Timothy J. Key, Kay-Tee Khaw, Marit Waaseth, Eiliv Lund, Elisabete Weiderpass, Eva Lundin, Annika Idahl, N. Charlotte Onland-Moret, Evelyn M. Monninkhof, H. Bas Bueno-de-Mesquita, Aurelio Barricarte, José María Huerta Castaño, Pilar Amiano, Esther Molina-Montes, Soledad Sánchez, Genevieve Buckland, Amalia Mattiello, Carlotta Sacerdote, Rosario Tumino, Claudia Agnoli, Giovanna Masala, Dimitrios Trichopoulos, Pagona Lagiou, Antonia Trichopoulou, Heiner Boeing, Isabelle Romieu, Sabina Rinaldi, Laura Baglietto, Kim Overvad, Anja Olsen, Anne Tjønneland, Françoise Clavel-Chapelon, Laure Dossus, Theron Johnson, Disorn Sookthai, and Kaja Tikk
- Abstract
Supplementary Table S1. Adjusteda geometric mean prolactin levels, ng/ml (95% CI) by established correlates at the time of blood donation. Supplementary Table S2. Adjusteda geometric mean prolactin levels, ng/ml (95% CI) depending on the anthropometric factors. Supplementary Table S3. Adjusteda geometric mean prolactin levels, ng/ml (95% CI) depending on the lifestyle factors.
- Published
- 2023
21. Supplementary Methods from Genetic Polymorphisms in 15q25 and 19q13 Loci, Cotinine Levels, and Risk of Lung Cancer in EPIC
- Author
-
Paul Brennan, Paolo Vineis, Elio Riboli, Göran Hallmans, Torgny Rasmuson, Dimitrios Trichopoulos, Pagona Lagiou, Antonia Trichopoulou, Rosario Tumino, Carlotta Sacerdote, Salvatore Panico, Giovanna Masala, Vittorio Krogh, Teresa Norat, Valentina Gallo, Ruth C. Travis, Naomi E. Allen, Nick Wareham, Kay-Tee Khaw, Nerea Larrañaga, Maria-José Sánchez, Laudina Rodríguez, Jose-Maria Huerta, Aurelio Barricarte, Antonio Agudo, Petra H.M. Peeters, Carla van Gils, H. Bas Bueno-de-Mesquita, Cornelia Weikert, Heiner Boeing, Birgit Teucher, Rudolf Kaaks, Guy Fagherazzi, Marie-Christine Boutron-Ruault, Françoise Clavel-Chapelon, Isabelle Romieu, Nadia Slimani, Ottar Nygård, Øivind Midttun, Stein Emil Vollset, Per Magne Ueland, Caroline Relton, Amélie Chabrier, Graham B. Byrnes, Mattias Johansson, Smith George Davey, James D. McKay, and Maria N. Timofeeva
- Abstract
PDF file - 82K
- Published
- 2023
22. Supplementary Tables 1-2 from Genetic Polymorphisms in 15q25 and 19q13 Loci, Cotinine Levels, and Risk of Lung Cancer in EPIC
- Author
-
Paul Brennan, Paolo Vineis, Elio Riboli, Göran Hallmans, Torgny Rasmuson, Dimitrios Trichopoulos, Pagona Lagiou, Antonia Trichopoulou, Rosario Tumino, Carlotta Sacerdote, Salvatore Panico, Giovanna Masala, Vittorio Krogh, Teresa Norat, Valentina Gallo, Ruth C. Travis, Naomi E. Allen, Nick Wareham, Kay-Tee Khaw, Nerea Larrañaga, Maria-José Sánchez, Laudina Rodríguez, Jose-Maria Huerta, Aurelio Barricarte, Antonio Agudo, Petra H.M. Peeters, Carla van Gils, H. Bas Bueno-de-Mesquita, Cornelia Weikert, Heiner Boeing, Birgit Teucher, Rudolf Kaaks, Guy Fagherazzi, Marie-Christine Boutron-Ruault, Françoise Clavel-Chapelon, Isabelle Romieu, Nadia Slimani, Ottar Nygård, Øivind Midttun, Stein Emil Vollset, Per Magne Ueland, Caroline Relton, Amélie Chabrier, Graham B. Byrnes, Mattias Johansson, Smith George Davey, James D. McKay, and Maria N. Timofeeva
- Abstract
PDF file - 57K
- Published
- 2023
23. Supplemental Material and Methods, Tables S1-S6, Figure S1 from Investigation of Dietary Factors and Endometrial Cancer Risk Using a Nutrient-wide Association Study Approach in the EPIC and Nurses' Health Study (NHS) and NHSII
- Author
-
Marc J. Gunter, Elio Riboli, Chirag J. Patel, Isabelle Romieu, Sabina Rinaldi, Ruth C. Travis, Nicholas Wareham, Kay-Tee Khaw, Annika Idahl, Lena Maria Nilsson, Emily Sonestedt, Ulrica Ericson, Saioa Chamosa, Aurelio Barricarte, D. Salmerón, María-José Sánchez, Eric J. Duell, J. Ramón Quirós, Guri Skeie, Inger T. Gram, Petra H. Peeters, N. Charlotte Onland-Moret, H.B(as). Bueno-de-Mesquita, Amalia Mattiello, Carlotta Sacerdote, Rosario Tumino, Sara Grioni, Domenico Palli, Dimitrios Trichopoulos, Christina Bamia, Antonia Trichopoulou, Heiner Boeing, Krasimira Aleksandrova, Rudolf Kaaks, Renée T. Fortner, Guy Fagherazzi, Marie-Christine Boutron-Ruault, Laure Dossus, Kim Overvad, Christina C. Dahm, Kristina E.N. Petersen, Anne Tjønneland, Elisabete Weiderpass, Konstantinos K. Tsilidis, Judy Fernandes, Susan E. Hankinson, Immaculata De Vivo, Shelley S. Tworoger, Ioanna Tzoulaki, and Melissa A. Merritt
- Abstract
Supplemental Material and Methods, Tables S1-S6, Figure S1 Supplemental Table S1. Hazard Ratiosa and 95% CIs from analyses of nutrient and food intakes (FDR≤0.10) reported in the baseline dietary assessment in relation to endometrial cancer risk in the EPIC study. Supplemental Table S2. Hazard Ratiosa and 95% CIs from analyses of intake of nutrients/foods at baseline (FDR > 0.10) in relation to endometrial cancer risk in the EPIC study. Supplemental Table S3. Age-standardized dietary intake of selected foods/nutrients (FDR≤0.10 in the EPIC studya) at the study baseline in the EPIC, NHS and NHSII study populations. Supplemental Table S4. Hazard Ratiosa and 95% CIs from analyses of intake of selected nutrients/foods at baseline in relation to endometrial cancer risk in the Nurses’ Health Study (NHS) and NHSII. Supplemental Table S5. Hazard Ratiosa and 95% CIs from analyses of the cumulative average intake of selected nutrients/foods in relation to endometrial cancer risk in the Nurses’ Health Study (NHS) and NHSII. Supplemental Table S6. Hazard Ratiosa and 95% CIs from analyses of the cumulative average intake of selected nutrients/foods in relation to invasive endometrial adenocarcinoma risk in the Nurses’ Health Study (NHS) and NHSII. Supplemental Figure S1. Summary of NWAS analytical method to test associations between food and nutrient intake and risk of endometrial cancer (EC.
- Published
- 2023
24. Data from Genetic Polymorphisms in 15q25 and 19q13 Loci, Cotinine Levels, and Risk of Lung Cancer in EPIC
- Author
-
Paul Brennan, Paolo Vineis, Elio Riboli, Göran Hallmans, Torgny Rasmuson, Dimitrios Trichopoulos, Pagona Lagiou, Antonia Trichopoulou, Rosario Tumino, Carlotta Sacerdote, Salvatore Panico, Giovanna Masala, Vittorio Krogh, Teresa Norat, Valentina Gallo, Ruth C. Travis, Naomi E. Allen, Nick Wareham, Kay-Tee Khaw, Nerea Larrañaga, Maria-José Sánchez, Laudina Rodríguez, Jose-Maria Huerta, Aurelio Barricarte, Antonio Agudo, Petra H.M. Peeters, Carla van Gils, H. Bas Bueno-de-Mesquita, Cornelia Weikert, Heiner Boeing, Birgit Teucher, Rudolf Kaaks, Guy Fagherazzi, Marie-Christine Boutron-Ruault, Françoise Clavel-Chapelon, Isabelle Romieu, Nadia Slimani, Ottar Nygård, Øivind Midttun, Stein Emil Vollset, Per Magne Ueland, Caroline Relton, Amélie Chabrier, Graham B. Byrnes, Mattias Johansson, Smith George Davey, James D. McKay, and Maria N. Timofeeva
- Abstract
Backgrounds: Multiple polymorphisms affecting smoking behavior have been identified through genome-wide association studies. Circulating levels of the nicotine metabolite cotinine is a marker of recent smoking exposure. Hence, genetic variants influencing smoking behavior are expected to be associated with cotinine levels.Methods: We conducted an analysis in a lung cancer case–control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. We investigated the effects of single-nucleotide polymorphisms (SNP) previously associated with smoking behavior on (i) circulating cotinine and (ii) lung cancer risk. A total of 894 cases and 1,805 controls were analyzed for cotinine and genotyped for 10 polymorphisms on 7p14, 8p11, 10q23, 15q25, and 19q13.Results: Two variants in the nicotinic acetylcholine receptor subunit genes CHRNA5 and CHRNA3 on 15q25, rs16969968 and rs578776, were associated with cotinine (P = 0.001 and 0.03, respectively) in current smokers and with lung cancer risk (P < 0.001 and P = 0.001, respectively). Two 19q13 variants, rs7937 and rs4105144, were associated with increased cotinine (P = 0.003 and P < 0.001, respectively) but decreased lung cancer risk (P = 0.01 for both, after adjusting for cotinine). Variants in 7p14, 8p11, and 10q23 were not associated with cotinine or lung cancer risk.Conclusions: 15q25 and 19q13 SNPs were associated with circulating cotinine. The directions of association for 15q25 variants with cotinine were in accordance with that expected of lung cancer risk, whereas SNPs on 19q13 displayed contrasting associations of cotinine and lung cancer that require further investigation.Impact: This study is the largest to date investigating the effects of polymorphisms affecting smoking behavior on lung cancer risk using circulating cotinine measures as proxies for recent smoking behavior. Cancer Epidemiol Biomarkers Prev; 20(10); 2250–61. ©2011 AACR.
- Published
- 2023
25. Data from Eighteen Insulin-like Growth Factor Pathway Genes, Circulating Levels of IGF-I and Its Binding Protein, and Risk of Prostate and Breast Cancer
- Author
-
Peter Kraft, Regina G. Ziegler, Elio Riboli, Rudolf Kaaks, Shumin M. Zhang, Meredith Yeager, Walter C. Willett, Stephanie J. Weinstein, Jarmo Virtamo, Rosario Tumino, Dimitrios Trichopoulos, Anne Tjønneland, Michael J. Thun, Gilles Thomas, Daniel O. Stram, Pär Stattin, Meir J. Stampfer, Maria-José Sánchez, Carlotta Sacerdote, Laudina Rodriguez, Kim Overvad, N. Charlotte Onland-Moret, Jing Ma, Eiliv Lund, Loic LeMarchand, I-Min Lee, Pagona Lagiou, Laurence N. Kolonel, Kay-Tee Khaw, Timothy J. Key, Mattias Johansson, Robert N. Hoover, David J. Hunter, Brian E. Henderson, Richard B. Hayes, Susan E. Hankinson, Christopher A. Haiman, Edward L. Giovannucci, J. Michael Gaziano, Vanessa Dumeaux, Françoise Clavel-Chapelon, Stephen J. Chanock, Nathalie Chabbert-Buffet, Julie E. Buring, H. Bas Bueno-de-Mesquita, Heiner Boeing, Sonja I. Berndt, Christine D. Berg, Demetrius Albanes, Naomi E. Allen, Federico Canzian, Fredrick R. Schumacher, and Fangyi Gu
- Abstract
Background: Circulating levels of insulin-like growth factor I (IGF-I) and its main binding protein, IGF binding protein 3 (IGFBP-3), have been associated with risk of several types of cancer. Heritable factors explain up to 60% of the variation in IGF-I and IGFBP-3 in studies of adult twins.Methods: We systematically examined common genetic variation in 18 genes in the IGF signaling pathway for associations with circulating levels of IGF-I and IGFBP-3. A total of 302 single nucleotide polymorphisms (SNP) were genotyped in >5,500 Caucasian men and 5,500 Caucasian women from the Breast and Prostate Cancer Cohort Consortium.Results: After adjusting for multiple testing, SNPs in the IGF1 and SSTR5 genes were significantly associated with circulating IGF-I (P < 2.1 × 10−4); SNPs in the IGFBP3 and IGFALS genes were significantly associated with circulating IGFBP-3. Multi-SNP models explained R2 = 0.62% of the variation in circulating IGF-I and 3.9% of the variation in circulating IGFBP-3. We saw no significant association between these multi-SNP predictors of circulating IGF-I or IGFBP-3 and risk of prostate or breast cancers.Conclusion: Common genetic variation in the IGF1 and SSTR5 genes seems to influence circulating IGF-I levels, and variation in IGFBP3 and IGFALS seems to influence circulating IGFBP-3. However, these variants explain only a small percentage of the variation in circulating IGF-I and IGFBP-3 in Caucasian men and women.Impact: Further studies are needed to explore contributions from other genetic factors such as rare variants in these genes and variation outside of these genes. Cancer Epidemiol Biomarkers Prev; 19(11); 2877–87. ©2010 AACR.
- Published
- 2023
26. Supplementary Table S3 from Shorter Leukocyte Telomere Length Is Independently Associated with Poor Survival in Patients with Bladder Cancer
- Author
-
Giuseppe Matullo, Carlotta Sacerdote, Paolo Vineis, Bruno Frea, Dario Fontana, Andrea Zitella, Luigi Rolle, Paolo Gontero, Paolo Destefanis, Giuseppina Cucchiarale, Giovanni Casetta, Andrea Bosio, Rossana Critelli, Alessandra Allione, Clara Viberti, Barbara Pardini, Giovanni Fiorito, Simonetta Guarrera, Federica Modica, and Alessia Russo
- Abstract
Supplementary Table S3. Multivariate Cox regression survival analysis, including TL, age, TG, BCG, radical cystectomy, radiotherapy and chemotherapy. All cause of death.
- Published
- 2023
27. Supplementary Table S1 from Shorter Leukocyte Telomere Length Is Independently Associated with Poor Survival in Patients with Bladder Cancer
- Author
-
Giuseppe Matullo, Carlotta Sacerdote, Paolo Vineis, Bruno Frea, Dario Fontana, Andrea Zitella, Luigi Rolle, Paolo Gontero, Paolo Destefanis, Giuseppina Cucchiarale, Giovanni Casetta, Andrea Bosio, Rossana Critelli, Alessandra Allione, Clara Viberti, Barbara Pardini, Giovanni Fiorito, Simonetta Guarrera, Federica Modica, and Alessia Russo
- Abstract
Supplementary Table S1. Description of populations included and not included in the TL study and comparative analysis.
- Published
- 2023
28. Supplementary Data from Prospective Identification of Elevated Circulating CDCP1 in Patients Years before Onset of Lung Cancer
- Author
-
Marc Chadeau-Hyam, Roel C.H. Vermeulen, Torkjel M. Sandanger, Mattias Johansson, Paolo Vineis, Augustin Scalbert, Pekka Keski-Rahkonen, Mikael Johansson, Matthias B. Schulze, Rosario Tumino, Salvatore Panico, Carlotta Sacerdote, Domenico Palli, Claudia Agnoli, Therese Haugdahl Nøst, Matthew D. Whitaker, Dusan Petrovic, Karl Smith-Byrne, Florence Guida, Barbara Bodinier, and Sonia Dagnino
- Abstract
Supplementary Methods, Figures and Tables.
- Published
- 2023
29. Supplementary Table 1 from Eighteen Insulin-like Growth Factor Pathway Genes, Circulating Levels of IGF-I and Its Binding Protein, and Risk of Prostate and Breast Cancer
- Author
-
Peter Kraft, Regina G. Ziegler, Elio Riboli, Rudolf Kaaks, Shumin M. Zhang, Meredith Yeager, Walter C. Willett, Stephanie J. Weinstein, Jarmo Virtamo, Rosario Tumino, Dimitrios Trichopoulos, Anne Tjønneland, Michael J. Thun, Gilles Thomas, Daniel O. Stram, Pär Stattin, Meir J. Stampfer, Maria-José Sánchez, Carlotta Sacerdote, Laudina Rodriguez, Kim Overvad, N. Charlotte Onland-Moret, Jing Ma, Eiliv Lund, Loic LeMarchand, I-Min Lee, Pagona Lagiou, Laurence N. Kolonel, Kay-Tee Khaw, Timothy J. Key, Mattias Johansson, Robert N. Hoover, David J. Hunter, Brian E. Henderson, Richard B. Hayes, Susan E. Hankinson, Christopher A. Haiman, Edward L. Giovannucci, J. Michael Gaziano, Vanessa Dumeaux, Françoise Clavel-Chapelon, Stephen J. Chanock, Nathalie Chabbert-Buffet, Julie E. Buring, H. Bas Bueno-de-Mesquita, Heiner Boeing, Sonja I. Berndt, Christine D. Berg, Demetrius Albanes, Naomi E. Allen, Federico Canzian, Fredrick R. Schumacher, and Fangyi Gu
- Abstract
Supplementary Table 1 from Eighteen Insulin-like Growth Factor Pathway Genes, Circulating Levels of IGF-I and Its Binding Protein, and Risk of Prostate and Breast Cancer
- Published
- 2023
30. Data from Inflammatory Markers and Risk of Epithelial Ovarian Cancer by Tumor Subtypes: The EPIC Cohort
- Author
-
Renée T. Fortner, Rudolf Kaaks, Elio Riboli, Marc J. Gunter, Melissa A. Merritt, Isabelle Romieu, Sabina Rinaldi, Kay-Tee Khaw, Ruth C. Travis, Annika Idahl, Eva Lundin, Jenny Brändstedt, Eva Ardanaz, José María Huerta Castaño, Nerea Larrañaga, Maria-José Sànchez-Pérez, Mireia Obon-Santacana, Soledad Sánchez, Inger T. Gram, Elisabete Weiderpass, N. Charlotte Onland-Moret, Petra H. M. Peeters, H. B(as). Bueno-de-Mesquita, Amalia Mattiello, Carlotta Sacerdote, Rosario Tumino, Giovanna Tagliabue, Giovanna Masala, Pagona Lagiou, Vassiliki Benetou, Antonia Trichopolou, Heiner Boeing, Laura Baglietto, Françoise Clavel-Chapelon, Laure Dossus, Kim Overvad, Louise Hansen, Anne Tjønneland, Helena Schock, and Jennifer Ose
- Abstract
Background: Evidence suggests an etiologic role for inflammation in ovarian carcinogenesis and heterogeneity between tumor subtypes and anthropometric indices. Prospective studies on circulating inflammatory markers and epithelial invasive ovarian cancer (EOC) have predominantly investigated overall risk; data characterizing risk by tumor characteristics (histology, grade, stage, dualistic model of ovarian carcinogenesis) and anthropometric indices are sparse.Methods: We conducted a nested case–control study in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort to evaluate C-reactive protein (CRP), IL6, and EOC risk by tumor characteristics. A total of 754 eligible EOC cases were identified; two controls (n = 1,497) were matched per case. We used multivariable conditional logistic regression to assess associations.Results: CRP and IL6 were not associated with overall EOC risk. However, consistent with prior research, CRP >10 versus CRP ≤1 mg/L was associated with higher overall EOC risk [OR, 1.67 (1.03–2.70)]. We did not observe significant associations or heterogeneity in analyses by tumor characteristics. In analyses stratified by waist circumference, inflammatory markers were associated with higher risk among women with higher waist circumference; no association was observed for women with normal waist circumference [e.g., IL6: waist ≤80: ORlog2, 0.97 (0.81–1.16); waist >88: ORlog2, 1.78 (1.28–2.48), Pheterogeneity ≤ 0.01].Conclusions: Our data suggest that high CRP is associated with increased risk of overall EOC, and that IL6 and CRP may be associated with EOC risk among women with higher adiposity.Impact: Our data add to global evidence that ovarian carcinogenesis may be promoted by an inflammatory milieu. Cancer Epidemiol Biomarkers Prev; 24(6); 951–61. ©2015 AACR.
- Published
- 2023
31. Data from Shorter Leukocyte Telomere Length Is Independently Associated with Poor Survival in Patients with Bladder Cancer
- Author
-
Giuseppe Matullo, Carlotta Sacerdote, Paolo Vineis, Bruno Frea, Dario Fontana, Andrea Zitella, Luigi Rolle, Paolo Gontero, Paolo Destefanis, Giuseppina Cucchiarale, Giovanni Casetta, Andrea Bosio, Rossana Critelli, Alessandra Allione, Clara Viberti, Barbara Pardini, Giovanni Fiorito, Simonetta Guarrera, Federica Modica, and Alessia Russo
- Abstract
Background: Shorter telomere length (TL) has been reported to be associated with increased risk of early death in elder individuals. Telomere shortening has been also related to chromosomal instability, which may possibly contribute to the development of several types of digestive or urogenital system cancers and smoking-related tumors. Therefore, we investigated the impact of TL on bladder cancer survival.Methods: TL was measured in leukocyte DNA from whole peripheral blood using quantitative real-time PCR in 463 patients with bladder cancer from a total 726 cases who were followed for up to 18 years.Results: Patients with muscle-invasive tumor/any grade had shorter telomere than patients with non–muscle-invasive tumor/high-grade and with non–muscle-invasive tumor/non–high-grade (TL reference 0.7 ± 0.2; vs. respectively, 0.8 ± 0.2, P = 3.4 × 10−2 and 0.8 ± 0.2, P = 3.6 × 10−2). Moreover, patients in the lowest quartiles of TL were associated with decreased survival after diagnosis (log-rank test, P = 3.9 × 10−4). A Cox regression adjusted by age, cancer aggressiveness, Bacillus Calmette-Guérin, radical cystectomy, radiotherapy, and chemotherapy showed an independent effect of TL on bladder cancer survival (HR, 3.9; 95% confidence interval, 1.7–9.1; P = 1.2 × 10−3).Conclusions: Our results suggest that leukocyte TL is only partly related to tumor aggressiveness and that shorter telomeres act as independent prognostic predictor of survival in patients with bladder cancer. TL information may allow to better select therapeutic approaches in patients with the same stage and grade.Impact: Blood leukocyte TL levels could provide an additional noninvasive prognostic marker to better predict survival and personalize therapies in patients with bladder cancer. Cancer Epidemiol Biomarkers Prev; 23(11); 2439–46. ©2014 AACR.
- Published
- 2023
32. Data from Polymorphisms in DNA Repair Genes, Smoking, and Bladder Cancer Risk: Findings from the International Consortium of Bladder Cancer
- Author
-
Montserrat Garcia-Closas, Sung Shim Lani Park, Cecilia Arici, Marcello Campagna, Angela Carta, Stefano Porru, Peter Rudnai, Rajiv Kumar, Kvetoslava Koppova, Eugen Gurzau, Alessandra Allione, Silvia Polidoro, Simonetta Guarrera, Carlotta Sacerdote, Paolo Vineis, Yu-Tang Gao, Yong-Bing Xiang, Victoria K. Cortessis, Manuela Gago-Dominguez, Amit D. Joshi, Román Corral, Faye Elliot, Jennifer H. Barrett, Ananya Choudhury, Sei Chung Sak, D. Timothy Bishop, Heather H. Nelson, Angeline S. Andrew, Margaret R. Karagas, Xifeng Wu, Stephen Chanock, Nuria Malats, Debra Silverman, Manolis Kogevinas, Nathaniel Rothman, Gunnar Steineck, Zuo-Feng Zhang, Donatella Placidi, Jack A. Taylor, Simone Benhamou, Tony Fletcher, Giuseppe Matullo, Jian-Min Yuan, Anne E. Kiltie, Karl T. Kelsey, Jonine D. Figueroa, Jie Lin, and Mariana C. Stern
- Abstract
Tobacco smoking is the most important and well-established bladder cancer risk factor and a rich source of chemical carcinogens and reactive oxygen species that can induce damage to DNA in urothelial cells. Therefore, common variation in DNA repair genes might modify bladder cancer risk. In this study, we present results from meta-analyses and pooled analyses conducted as part of the International Consortium of Bladder Cancer. We included data on 10 single nucleotide polymorphisms corresponding to seven DNA repair genes from 13 studies. Pooled analyses and meta-analyses included 5,282 cases and 5,954 controls of non-Latino white origin. We found evidence for weak but consistent associations with ERCC2 D312N [rs1799793; per-allele odds ratio (OR), 1.10; 95% confidence interval (95% CI), 1.01–1.19; P = 0.021], NBN E185Q (rs1805794; per-allele OR, 1.09; 95% CI, 1.01–1.18; P = 0.028), and XPC A499V (rs2228000; per-allele OR, 1.10; 95% CI, 1.00–1.21; P = 0.044). The association with NBN E185Q was limited to ever smokers (interaction P = 0.002) and was strongest for the highest levels of smoking dose and smoking duration. Overall, our study provides the strongest evidence to date for a role of common variants in DNA repair genes in bladder carcinogenesis. [Cancer Res 2009;69(17):6857–64]
- Published
- 2023
33. Supplementary Tables 1-8 from Polymorphisms in DNA Repair Genes, Smoking, and Bladder Cancer Risk: Findings from the International Consortium of Bladder Cancer
- Author
-
Montserrat Garcia-Closas, Sung Shim Lani Park, Cecilia Arici, Marcello Campagna, Angela Carta, Stefano Porru, Peter Rudnai, Rajiv Kumar, Kvetoslava Koppova, Eugen Gurzau, Alessandra Allione, Silvia Polidoro, Simonetta Guarrera, Carlotta Sacerdote, Paolo Vineis, Yu-Tang Gao, Yong-Bing Xiang, Victoria K. Cortessis, Manuela Gago-Dominguez, Amit D. Joshi, Román Corral, Faye Elliot, Jennifer H. Barrett, Ananya Choudhury, Sei Chung Sak, D. Timothy Bishop, Heather H. Nelson, Angeline S. Andrew, Margaret R. Karagas, Xifeng Wu, Stephen Chanock, Nuria Malats, Debra Silverman, Manolis Kogevinas, Nathaniel Rothman, Gunnar Steineck, Zuo-Feng Zhang, Donatella Placidi, Jack A. Taylor, Simone Benhamou, Tony Fletcher, Giuseppe Matullo, Jian-Min Yuan, Anne E. Kiltie, Karl T. Kelsey, Jonine D. Figueroa, Jie Lin, and Mariana C. Stern
- Abstract
Supplementary Tables 1-8 from Polymorphisms in DNA Repair Genes, Smoking, and Bladder Cancer Risk: Findings from the International Consortium of Bladder Cancer
- Published
- 2023
34. Supplementary Figure Legend from Polymorphisms in DNA Repair Genes, Smoking, and Bladder Cancer Risk: Findings from the International Consortium of Bladder Cancer
- Author
-
Montserrat Garcia-Closas, Sung Shim Lani Park, Cecilia Arici, Marcello Campagna, Angela Carta, Stefano Porru, Peter Rudnai, Rajiv Kumar, Kvetoslava Koppova, Eugen Gurzau, Alessandra Allione, Silvia Polidoro, Simonetta Guarrera, Carlotta Sacerdote, Paolo Vineis, Yu-Tang Gao, Yong-Bing Xiang, Victoria K. Cortessis, Manuela Gago-Dominguez, Amit D. Joshi, Román Corral, Faye Elliot, Jennifer H. Barrett, Ananya Choudhury, Sei Chung Sak, D. Timothy Bishop, Heather H. Nelson, Angeline S. Andrew, Margaret R. Karagas, Xifeng Wu, Stephen Chanock, Nuria Malats, Debra Silverman, Manolis Kogevinas, Nathaniel Rothman, Gunnar Steineck, Zuo-Feng Zhang, Donatella Placidi, Jack A. Taylor, Simone Benhamou, Tony Fletcher, Giuseppe Matullo, Jian-Min Yuan, Anne E. Kiltie, Karl T. Kelsey, Jonine D. Figueroa, Jie Lin, and Mariana C. Stern
- Abstract
Supplementary Figure Legend from Polymorphisms in DNA Repair Genes, Smoking, and Bladder Cancer Risk: Findings from the International Consortium of Bladder Cancer
- Published
- 2023
35. Supplementary Figure 1 from Polymorphisms in DNA Repair Genes, Smoking, and Bladder Cancer Risk: Findings from the International Consortium of Bladder Cancer
- Author
-
Montserrat Garcia-Closas, Sung Shim Lani Park, Cecilia Arici, Marcello Campagna, Angela Carta, Stefano Porru, Peter Rudnai, Rajiv Kumar, Kvetoslava Koppova, Eugen Gurzau, Alessandra Allione, Silvia Polidoro, Simonetta Guarrera, Carlotta Sacerdote, Paolo Vineis, Yu-Tang Gao, Yong-Bing Xiang, Victoria K. Cortessis, Manuela Gago-Dominguez, Amit D. Joshi, Román Corral, Faye Elliot, Jennifer H. Barrett, Ananya Choudhury, Sei Chung Sak, D. Timothy Bishop, Heather H. Nelson, Angeline S. Andrew, Margaret R. Karagas, Xifeng Wu, Stephen Chanock, Nuria Malats, Debra Silverman, Manolis Kogevinas, Nathaniel Rothman, Gunnar Steineck, Zuo-Feng Zhang, Donatella Placidi, Jack A. Taylor, Simone Benhamou, Tony Fletcher, Giuseppe Matullo, Jian-Min Yuan, Anne E. Kiltie, Karl T. Kelsey, Jonine D. Figueroa, Jie Lin, and Mariana C. Stern
- Abstract
Supplementary Figure 1 from Polymorphisms in DNA Repair Genes, Smoking, and Bladder Cancer Risk: Findings from the International Consortium of Bladder Cancer
- Published
- 2023
36. Risk of myocardial infarction and stroke after female breast cancer: analysis on a cohort of 1.3 million women
- Author
-
Fulvio Ricceri, Enrica Favaro, Gregory Winston Gilcrease, Sara Claudia Calabrese, Elisa Ferracin, Daniela Di Cuonzo, Alessandra Macciotta, Alberto Catalano, Lucia Dansero, Angelo d’Errico, Pierfrancesco Franco, Gianmauro Numico, Roberto Gnavi, Giuseppe Costa, Eva Pagano, and Carlotta Sacerdote
- Abstract
Background Breast Cancer (BC) is a leading public-health issue affecting women on a global scale, accounting for about 500,000 new cases every year in Europe. Thanks to the widespread implementation of screening programs and the improvement in therapies, women with BC live longer but they also are more likely to experience an increased risk of other diseases, including second primary cancer, cardiovascular, and metabolic diseases. Reasons for this increased risk include genetics, shared risk factors, and adverse effects from BC treatment. Methods To analyse the risk of myocardial infarction (MI) and stroke in women with BC considering the potential side effects of treatments, we used data from the Piedmont Longitudinal Study, an administrative cohort based on the record-linkage among census data and several health-administrative databases to include than 4 million inhabitants of an Italian region. Results Among 1,342,333 women ranging from 30 to 75 years old 19,203 had a BC diagnosis in the follow-up period, of whom 206 experienced a subsequent MI and 203 a stroke. Women with BC showed an increased risk for MI (HR: 1.20; 95%CI: 1.05–1.38) and for stroke (HR: 1.58; 95%CI: 1.38–1.82). Chemotherapy seemed to be the major risk factor for MI in BC women, while no different risk by therapy was found for stroke. Conclusion The results of this study supported the hypothesis about the toxic effect of therapies, suggesting both clinicians to routinely and actively screen for these treatment-related toxicities in women with BC and researchers to prioritize personalized treatments in order to minimize potentially devastating side effects.
- Published
- 2023
37. Physical activity attenuates but does not eliminate coronary heart disease risk amongst adults with risk factors: EPIC-CVD case-cohort study
- Author
-
Melony C Fortuin-de Smidt, Maquins Odhiambo Sewe, Camille Lassale, Elisabete Weiderpass, Jonas Andersson, José María Huerta, Ulf Ekelund, Krasimira Aleksandrova, Tammy YN Tong, Christina C Dahm, Anne Tjønneland, Cecilie Kyrø, Karen Steindorf, Matthias B Schulze, Verena Katzke, Carlotta Sacerdote, Claudia Agnoli, Giovanna Masala, Rosario Tumino, Salvatore Panico, Jolanda MA Boer, N Charlotte Onland-Moret, GC Wanda Wendel-Vos, Yvonne T van der Schouw, Kristin Benjaminsen Borch, Antonio Agudo, Dafina Petrova, María Dolores Chirlaque, Moreno Iribas Conchi, Pilar Amiano, Olle Melander, Alicia K Heath, Dagfinn Aune, Nita G Forouhi, Claudia Langenberg, Soren Brage, Elio Riboli, Nicholas J Wareham, John Danesh, Adam S Butterworth, Patrik Wennberg, Forouhi, Nita [0000-0002-5041-248X], Langenberg, Claudia [0000-0002-5017-7344], Brage, Soren [0000-0002-1265-7355], Wareham, Nicholas [0000-0003-1422-2993], Danesh, John [0000-0003-1158-6791], Butterworth, Adam [0000-0002-6915-9015], and Apollo - University of Cambridge Repository
- Subjects
Adult ,Cardiac & Cardiovascular Systems ,population preventable fraction ,Epidemiology ,Hypercholesterolemia ,QUESTIONNAIRE ,physical activity ,BLOOD-PRESSURE ,EXERCISE ,Coronary Disease ,ALL-CAUSE ,Cohort Studies ,Risk Factors ,Humans ,risk factors ,Obesity ,Prospective Studies ,coronary heart disease ,Exercise ,POPULATION ,Science & Technology ,Physical activity ,MORTALITY ,Incidence ,Public Health, Global Health, Social Medicine and Epidemiology ,ASSOCIATION ,PREVENTION ,case-cohort study ,Coronary heart disease ,Population preventable fraction ,Risk factors ,Case-cohort study ,Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi ,CARDIOVASCULAR-DISEASE ,Hypertension ,Cardiovascular System & Cardiology ,LIFE-STYLE ,Cardiology and Cardiovascular Medicine ,Life Sciences & Biomedicine - Abstract
Aims This study aimed to evaluate the association between physical activity and the incidence of coronary heart disease (CHD) in individuals with and without CHD risk factors. Methods and results EPIC-CVD is a case-cohort study of 29 333 participants that included 13 582 incident CHD cases and a randomly selected sub-cohort nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Self-reported physical activity was summarized using the Cambridge physical activity index (inactive, moderately inactive, moderately active, and active). Participants were categorized into sub-groups based on the presence or the absence of the following risk factors: obesity (body mass index ≥30 kg/m2), hypercholesterolaemia (total cholesterol ≥6.2 mmol/L), history of diabetes, hypertension (self-reported or ≥140/90 mmHg), and current smoking. Prentice-weighted Cox regression was used to assess the association between physical activity and incident CHD events (non-fatal and fatal). Compared to inactive participants without the respective CHD risk factor (referent), excess CHD risk was highest in physically inactive and lowest in moderately active participants with CHD risk factors. Corresponding excess CHD risk estimates amongst those with obesity were 47% [95% confidence interval (CI) 32–64%] and 21% (95%CI 2–44%), with hypercholesterolaemia were 80% (95%CI 55–108%) and 48% (95%CI 22–81%), with hypertension were 80% (95%CI 65–96%) and 49% (95%CI 28–74%), with diabetes were 142% (95%CI 63–260%), and 100% (95%CI 32–204%), and amongst smokers were 152% (95%CI 122–186%) and 109% (95%CI 74–150%). Conclusions In people with CHD risk factors, moderate physical activity, equivalent to 40 mins of walking per day, attenuates but does not completely offset CHD risk.
- Published
- 2022
38. Inflammatory potential of diet and pancreatic cancer risk in the EPIC study
- Author
-
Valerie Cayssials, Genevieve Buckland, Marta Crous-Bou, Catalina Bonet, Elisabete Weiderpass, Guri Skie, Dagfinn Aune, Alicia Heath, Therese Haugdahl Nøst, Giovanna Masala, Claudia Agnoli, Maria Santucci De Magistris, Bas Bueno-de-Mesquita, Jeroen Derksen, Inge Huybrechts, Pietro Ferrari, Oscar Franklin, Stina Bodén, Matthias Schulze, Jose Maria Huerta, Aurelio Barricarte, Carlotta Sacerdote, Pilar Amiano, Rosario Tumino, Esther Molina-Montes, Anne Tjønneland, Cecilie Kyrø, Gianluca Severi, Marie-Christine Boutron-Ruault, Vinciane Rebours, Verena Katzke, Antonio Agudo, and Paula Jakszyn
- Subjects
Pancreatic Neoplasms ,Nutrition and Dietetics ,Risk Factors ,Humans ,Nutritional Status ,Medicine (miscellaneous) ,Prospective Studies ,Diet - Abstract
There is existing evidence on the potential role of chronic inflammation in the pathogenesis of pancreatic cancer (PC) and on how risk may be modulated by dietary factors. Pro-inflammatory diets are suggested to be associated with increased risk of PC but, so far, evidence remains not conclusive. We examined the association between the dietary inflammatory potential and PC risk within the European Prospective Investigation into Cancer and Nutrition (EPIC) study, which includes 450,112 participants.After a 14-year follow-up, a total of 1239 incident PC cases were included in this study. The inflammatory potential of the diet was estimated using an Inflammatory Score of the Diet (ISD). Hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between the ISD and PC were estimated using multivariable Cox regression models, adjusted for known risk factors for PC.Participants with higher ISDs had a higher risk of developing PCs. In the fully adjusted multivariate model, the risk of PC increased by 11% (HR 1.11, 95% CI 1.02-1.22) for 1 point each standard deviation increase in the ISD score. Neither obesity nor any other known risk factor for PC showed statistically significant interactions.To the best of our knowledge, this is the first prospective study reporting a positive relationship between the inflammatory potential of diet and PC. Since early diagnosis and treatment of pancreatic cancer might be challenging, prevention remains the major hope for reducing the burden of this disease.
- Published
- 2022
39. Dietary Intake of 91 Individual Polyphenols and 5-Year Body Weight Change in the EPIC-PANACEA Cohort
- Author
-
Mercedes Gil-Lespinard, Jazmín Castañeda, Enrique Almanza-Aguilera, Jesús Humberto Gómez, Anne Tjønneland, Cecilie Kyrø, Kim Overvad, Verena Katzke, Matthias B. Schulze, Giovanna Masala, Claudia Agnoli, Maria Santucci de Magistris, Rosario Tumino, Carlotta Sacerdote, Guri Skeie, Cristina Lasheras, Esther Molina-Montes, José María Huerta, Aurelio Barricarte, Pilar Amiano, Emily Sonestedt, Marisa da Silva, Ingegerd Johansson, Johan Hultdin, Anne M. May, Nita G. Forouhi, Alicia K. Heath, Heinz Freisling, Elisabete Weiderpass, Augustin Scalbert, Raul Zamora-Ros, Almanza-Aguilera, Enrique [0000-0002-4805-0774], Kyrø, Cecilie [0000-0002-9083-8960], Masala, Giovanna [0000-0002-5758-9069], Tumino, Rosario [0000-0003-2666-414X], Sacerdote, Carlotta [0000-0002-8008-5096], Skeie, Guri [0000-0003-2476-4251], Molina-Montes, Esther [0000-0002-0428-2426], Huerta, José María [0000-0002-9637-3869], Sonestedt, Emily [0000-0002-0747-4562], da Silva, Marisa [0000-0003-1215-8625], Johansson, Ingegerd [0000-0002-9227-8434], Hultdin, Johan [0000-0002-9599-0961], Heath, Alicia K [0000-0001-6517-1300], Freisling, Heinz [0000-0001-8648-4998], Weiderpass, Elisabete [0000-0003-2237-0128], Zamora-Ros, Raul [0000-0002-6236-6804], and Apollo - University of Cambridge Repository
- Subjects
obesity ,Nutrition and Dietetics ,polyphenol ,intake ,body weight ,cohort ,EPIC ,Physiology ,Estrès oxidatiu ,Clinical Biochemistry ,Pes corporal ,Polyphenols ,Cell Biology ,Biochemistry ,Article ,Näringslära ,Oxidative stress ,Polifenols ,Obesitat ,Molecular Biology - Abstract
Peer reviewed: True, Funder: International Agency for Research on Cancer (IARC), Funder: Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, Funder: NIHR Imperial Biomedical Research Centre (BRC), Funder: Danish Cancer Society (Denmark), Funder: Ligue Contre le Cancer, Funder: Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Funder: Institut National de la Santé et de la Recherche Médicale (INSERM), Funder: German Cancer Aid, Funder: German Cancer Research Center (DKFZ), Funder: German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Funder: Federal Ministry of Education and Research (BMBF), Funder: Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Funder: Compagnia di San Paolo, Funder: National Research Council, Funder: Dutch Ministry of Public Health, Welfare and Sports (VWS), Funder: Netherlands Cancer Registry (NKR), Funder: LK Research Funds, Funder: Dutch Prevention Funds, Funder: Dutch ZON (Zorg Onderzoek Nederland), Funder: World Cancer Research Fund (WCRF), Funder: Statistics Netherlands, Funder: Health Research Fund (FIS)—Instituto de Salud Carlos III (ISCIII), Funder: Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, Funder: Catalan Institute of Oncology—ICO, Funder: Swedish Cancer Society, Funder: Swedish Research Council, Funder: County Councils of Skåne and Västerbotten, Polyphenols are bioactive compounds from plants with antioxidant properties that may have a protective role against body weight gain, with adipose tissue and systemic oxidative stress as potential targets. We aimed to investigate the dietary intake of individual polyphenols and their association with 5-year body weight change in a sub-cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC). This study included 349,165 adult participants from nine European countries. Polyphenol intake was estimated through country-specific validated dietary questionnaires and the Phenol-Explorer database. Body weight was obtained at recruitment and after a mean follow-up time of 5 years. Associations were estimated using multilevel mixed linear regression models. From 91 polyphenols included, the majority (n = 67) were inversely associated with 5-year body weight change after FDR-correction (q < 0.05). The greatest inverse associations were observed for quercetin 3-O-rhamnoside (change in weight for doubling in intake: -0.071 (95% CI: -0.085; -0.056) kg/5 years). Only 13 polyphenols showed positive associations with body weight gain, mainly from the subclass hydroxycinnamic acids (HCAs) with coffee as the main dietary source, such as 4-caffeoylquinic acid (0.029 (95% CI: 0.021; 0.038) kg/5 years). Individual polyphenols with fruit, tea, cocoa and whole grain cereals as the main dietary sources may contribute to body weight maintenance in adults. Individual HCAs may have different roles in body weight change depending on their dietary source.
- Published
- 2023
- Full Text
- View/download PDF
40. Are Circulating Immune Cells a Determinant of Pancreatic Cancer Risk? A Prospective Study Using Epigenetic Cell Count Measures
- Author
-
Matthias B. Schulze, Anne Tjønneland, Laure Dossus, Sofia Christakoudi, Kim Overvad, Verena Katzke, Roel Vermeulen, Giovanna Masala, Pilar Amiano, Elisabete Weiderpass, José María Huerta, Anja Olsen, Federico Canzian, Valeria Pala, Theron Johnson, Oskar Franklin, Charlotte Le Cornet, Marie-Christine Boutron-Ruault, Salvatore Panico, Eva Ardanaz, Rosario Tumino, Esther Molina-Montes, Bas Bueno-de-Mesquita, Marta Crous-Bou, Sven Olek, Rayaan Mahfouz, Rudolf Kaaks, Aurora Perez-Cornago, Bianca Brauer, Gianluca Severi, Carlotta Sacerdote, Vinciane Rebours, and Malin Sund
- Subjects
Adult ,Male ,Neutrophils ,Epidemiology ,Lymphocyte ,pancreatic cancer ,T-Lymphocytes, Regulatory ,Epigenesis, Genetic ,Immune system ,neutrophils ,Pancreatic cancer ,Biomarkers, Tumor ,Humans ,T-lymphocyte subsets ,Cytotoxic T cell ,Medicine ,Lymphocyte Count ,Prospective Studies ,Prospective cohort study ,Aged ,Aged, 80 and over ,business.industry ,FOXP3 ,Middle Aged ,medicine.disease ,European Prospective Investigation into Cancer and Nutrition ,Causality ,Pancreatic Neoplasms ,EPIC study ,immune system ,medicine.anatomical_structure ,Oncology ,Case-Control Studies ,Immunology ,Female ,business ,CD8 - Abstract
Background: Evidence is accumulating that immune cells play a prominent role in pancreatic cancer etiology but prospective investigations are missing. Methods: We conducted a nested case–control study within the European Prospective Investigation into Cancer and Nutrition (EPIC) study with 502 pairs of incident pancreatic cancer cases and matched controls. Relative counts of circulating immune cells (neutrophils and lymphocyte sublineages: total CD3+, CD8+, CD4+, and FOXP3+ regulatory T cells (Tregs) relative to nucleated cells, (white blood cells) were measured by qRT-PCR. ORs with 95% confidence intervals were estimated using logistic regressions, modeling relative counts of immune cells on a continuous scale. Results: Neither relative counts of immune cell types taken individually, nor mutually adjusted for each other were associated with pancreatic cancer risks. However, in subgroup analyses by strata of lag-time, higher relative counts of Tregs and lower relative counts of CD8+ were significantly associated with an increased pancreatic cancer risks in participants diagnosed within the first 5 years of follow-up. Conclusions: These results might reflect reverse causation, due to higher relative counts of Tregs and lower counts of CD8+ cells among individuals with more advanced stages of latent pancreatic cancer, who are closer to the point of developing clinical manifest disease. Impact: We have shown, for the first time, that increased relative counts of regulatory T cells and lower relative counts of CD8+, cytotoxic T cells may be associated with pancreatic cancer risk or relatively late-stage tumor development. See related commentary by Michaud and Kelsey, p. 2176
- Published
- 2021
41. Are antigenic tests useful for detecting SARS-CoV-2 infections in patients accessing to emergency departments? Results from a North-West Italy hospital
- Author
-
Vittoria Basile, Alberto Catalano, Giuseppe Costa, Paolo Vineis, Carlotta Sacerdote, Fulvio Ricceri, Anita Ferraro, Adriana Boccuzzi, Valeria Caramello, and Alessandra Macciotta
- Subjects
Microbiology (medical) ,Emergency Service ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Emergency department ,SARS-CoV-2 ,business.industry ,Antigenic tests ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,COVID-19 ,Negative predictive value ,Virology ,Hospitals ,Hospital ,Infectious Diseases ,Italy ,North west ,Emergency Service, Hospital ,Humans ,Medicine ,In patient ,business ,Letter to the Editor - Published
- 2021
42. The cost-effectiveness of a uniform versus age-based threshold for one-off screening for prevention of cardiovascular disease
- Author
-
Zuzana Špacírová, Stephen Kaptoge, Leticia García-Mochón, Miguel Rodríguez Barranco, María José Sánchez Pérez, Nicola P. Bondonno, Anne Tjønneland, Elisabete Weiderpass, Sara Grioni, Jaime Espín, Carlotta Sacerdote, Catarina Schiborn, Giovanna Masala, Sandra M. Colorado-Yohar, Lois Kim, Karel G. M. Moons, Gunnar Engström, Matthias B. Schulze, Léa Bresson, Concepción Moreno-Iribas, David Epstein, Špacírová, Zuzana [0000-0002-2905-2934], and Apollo - University of Cambridge Repository
- Subjects
Spain ,Health Policy ,Economics, Econometrics and Finance (miscellaneous) ,Screening ,Statins ,Cost-effectiveness ,Framingham risk score ,Cardiovascular disease - Abstract
The objective of this article was to assess the cost-effectiveness of screening strategies for cardiovascular diseases (CVD). A decision analytic model was constructed to estimate the costs and benefits of one-off screening strategies differentiated by screening age, sex and the threshold for initiating statin therapy ("uniform" or "age-adjusted") from the Spanish NHS perspective. The age-adjusted thresholds were configured so that the same number of people at high risk would be treated as under the uniform threshold. Health benefit was measured in quality-adjusted life years (QALY). Transition rates were estimated from the European Prospective Investigation into Cancer and Nutrition (EPIC-CVD), a large multicentre nested case-cohort study with 12 years of follow-up. Unit costs of primary care, hospitalizations and CVD care were taken from the Spanish health system. Univariate and probabilistic sensitivity analyses were employed. The comparator was no systematic screening program. The base case model showed that the most efficient one-off strategy is to screen both men and women at 40 years old using a uniform risk threshold for initiating statin treatment (Incremental Cost-Effectiveness Ratio of €3,274/QALY and €6,085/QALY for men and women, respectively). Re-allocating statin treatment towards younger individuals at high risk for their age and sex would not offset the benefit obtained using those same resources to treat older individuals. Results are sensitive to assumptions about CVD incidence rates. To conclude, one-off screening for CVD using a uniform risk threshold appears cost-effective compared with no systematic screening. These results should be evaluated in clinical studies.
- Published
- 2022
43. Methylation-based markers of aging and lifestyle-related factors and risk of breast cancer: a pooled analysis of four prospective studies
- Author
-
Pierre-Antoine Dugué, Clara Bodelon, Felicia F. Chung, Hannah R. Brewer, Srikant Ambatipudi, Joshua N. Sampson, Cyrille Cuenin, Veronique Chajès, Isabelle Romieu, Giovanni Fiorito, Carlotta Sacerdote, Vittorio Krogh, Salvatore Panico, Rosario Tumino, Paolo Vineis, Silvia Polidoro, Laura Baglietto, Dallas English, Gianluca Severi, Graham G. Giles, Roger L. Milne, Zdenko Herceg, Montserrat Garcia-Closas, James M. Flanagan, Melissa C. Southey, Monash University [Clayton], National Cancer Institute [Bethesda] (NCI-NIH), National Institutes of Health [Bethesda] (NIH), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, National Institutes of Health, NIH, National Cancer Institute, NCI, Breast Cancer Now, BCN, Division of Cancer Epidemiology and Genetics, National Cancer Institute, DCEG, European Commission, EC, National Health and Medical Research Council, NHMRC: 1011618, 1164455, Fondation ARC pour la Recherche sur le Cancer, ARC, Ligue Contre le Cancer, Seventh Framework Programme, FP7, Institut National Du Cancer, INCa, Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer/World Health Organization., This research was partially supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics. The work performed by the Epigenomics and Mechanisms Branch at IARC was supported by grants from the Institut National du Cancer (INCa, France), the European Commission (EC) Seventh Framework Programme (FP7) Translational Cancer Research (TRANSCAN) Framework, the Fondation ARC pour la Recherche sur le Cancer (France), and la Ligue Nationale (Française) Contre le Cancer to ZH. The MCCS methylation work was supported by the National Health and Medical Research Council (grant numbers 1011618 and 1164455) and the Victorian Breast Cancer Research Consortium. The work performed at Imperial College London was funded by Breast Cancer Now and supported by the Cancer Research UK Imperial Centre, the National Institute for Health Research Imperial Biomedical Research Centre and the Ovarian Cancer Action Research Centre. MCS is a National Health and Medical Research Council Senior Research Fellow (GNT1155163)., and HAL UVSQ, Équipe
- Subjects
Aging ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Breast Neoplasms ,DNA Methylation ,Lifestyle ,Epigenesis, Genetic ,Epigenetic aging ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,Risk Factors ,Prospective study DNA methylation Epigenetic aging Lifestyle Breast cancer risk ,Humans ,Female ,Prospective Studies ,Prospective study ,Breast cancer risk ,Life Style - Abstract
Background DNA methylation in blood may reflect adverse exposures accumulated over the lifetime and could therefore provide potential improvements in the prediction of cancer risk. A substantial body of research has shown associations between epigenetic aging and risk of disease, including cancer. Here we aimed to study epigenetic measures of aging and lifestyle-related factors in association with risk of breast cancer. Methods Using data from four prospective case–control studies nested in three cohorts of European ancestry participants, including a total of 1,655 breast cancer cases, we calculated three methylation-based measures of lifestyle factors (body mass index [BMI], tobacco smoking and alcohol consumption) and seven measures of epigenetic aging (Horvath-based, Hannum-based, PhenoAge and GrimAge). All measures were regression-adjusted for their respective risk factors and expressed per standard deviation (SD). Odds ratios (OR) and 95% confidence intervals (CI) were calculated using conditional or unconditional logistic regression and pooled using fixed-effects meta-analysis. Subgroup analyses were conducted by age at blood draw, time from blood sample to diagnosis, oestrogen receptor-positivity status and tumour stage. Results None of the measures of epigenetic aging were associated with risk of breast cancer in the pooled analysis: Horvath ‘age acceleration’ (AA): OR per SD = 1.02, 95%CI: 0.95–1.10; AA-Hannum: OR = 1.03, 95%CI:0.95–1.12; PhenoAge: OR = 1.01, 95%CI: 0.94–1.09 and GrimAge: OR = 1.03, 95%CI: 0.94–1.12, in models adjusting for white blood cell proportions, body mass index, smoking and alcohol consumption. The BMI-adjusted predictor of BMI was associated with breast cancer risk, OR per SD = 1.09, 95%CI: 1.01–1.17. The results for the alcohol and smoking methylation-based predictors were consistent with a null association. Risk did not appear to substantially vary by age at blood draw, time to diagnosis or tumour characteristics. Conclusion We found no evidence that methylation-based measures of aging, smoking or alcohol consumption were associated with risk of breast cancer. A methylation-based marker of BMI was associated with risk and may provide insights into the underlying associations between BMI and breast cancer.
- Published
- 2022
44. Investigating the role of circulating miRNAs as biomarkers in colorectal cancer: an epidemiological systematic review
- Author
-
Carlotta Sacerdote
- Abstract
Review question / Objective: What is the potential role of microRNAs as biomarkers of colorectal cancer. Eligibility criteria: Studies were considered eligible for the systematic review if they met the following criteria: 1) study patients have been diagnosed with CRC; 2) healthy individuals were used as controls; 3) biological samples were plasma or serum or blood; 4) results included any of AUC, sensitivity, and specificity and/or fold change values. Studies were excluded if they were: 1) reviews, meta-analyses, conference abstracts, letters; 2) animals or cells experiments; 3) studies that investigated prognosis, survival, or metastatic cancers only; 4) studies that investigated toxicity or therapy efficacy; 5) studies with insufficient data; 6) studies not published in English language.
- Published
- 2022
45. Food Processing and Risk of Crohn's Disease and Ulcerative Colitis: A European Prospective Cohort Study
- Author
-
Antoine Meyer, Catherine Dong, Corinne Casagrande, Simon S.M. Chan, Inge Huybrechts, Geneviève Nicolas, Fernanda Rauber, Renata Bertazzi Levy, Christopher Millett, Bas Oldenburg, Elisabete Weiderpass, Alicia K. Heath, Tammy Y.N. Tong, Anne Tjønneland, Cecilie Kyrø, Rudolf Kaaks, Verena A. Katzke, Manuela M. Bergman, Domenico Palli, Giovanna Masala, Rosario Tumino, Carlotta Sacerdote, Sandra M. Colorado-Yohar, Maria-Jose Sánchez, Olof Grip, Stefan Lindgren, Robert Luben, Marc J. Gunter, Yahya Mahamat-Saleh, Marie-Christine Boutron-Ruault, and Franck Carbonnel
- Subjects
Hepatology ,Gastroenterology - Abstract
Industrial foods have been associated with increased risks of several chronic conditions. We investigated the relationship between the degree of food processing and risks of Crohn's disease (CD) and ulcerative colitis (UC) in the European Prospective Investigation into Cancer and Nutrition cohort.Analyses included 413,590 participants (68.6% women; mean baseline age, 51.7 y) from 8 European countries. Dietary data were collected at baseline from validated country-specific dietary questionnaires. Associations between proportions of unprocessed/minimally processed and ultraprocessed food intake and CD and UC risks were estimated using Cox models to obtain hazard ratios (HRs) and 95% CIs. Models were stratified by center, age, and sex, and adjusted for smoking status, body mass index, physical activity, energy intake, educational level, and alcohol consumption.During a mean follow-up period of 13.2 years, 179 incident cases of CD and 431 incident cases of UC were identified. The risk of CD was lower in people consuming high proportions of unprocessed/minimally processed foods (adjusted HR for the highest vs lowest quartile: 0.57; 95% CI, 0.35-0.93; P trend.01), particularly fruits and vegetables (adjusted HRs, 0.54; 95% CI, 0.34-0.87 and 0.55; 95% CI, 0.34-0.91, respectively). There was no association between unprocessed/minimally processed food intake and the risk of UC. No association was detected between ultraprocessed food consumption and CD or UC risks.In the European Prospective Investigation into Cancer and Nutrition cohort, consumption of unprocessed/minimally processed foods was associated with a lower risk of CD. No association between UC risk and food processing was found.
- Published
- 2022
46. Health status assessment of a population of asylum seekers in Northern Italy
- Author
-
Luca Manfredi, Veronica Sciannameo, Cinzia Destefanis, Marta Prisecaru, Giorgia Cossu, Roberto Gnavi, Alessandra Macciotta, Alberto Catalano, Roberto Raffaele Pepe, Carlotta Sacerdote, and Fulvio Ricceri
- Subjects
Adult ,Male ,Refugees ,Adolescent ,Asylum seekers ,Health Status ,Health Policy ,Public Health, Environmental and Occupational Health ,Migrants diseases ,Migrants health ,Migration ,Migration in Italy ,Africa South of the Sahara ,Cross-Sectional Studies ,Female ,Humans ,Italy ,Retrospective Studies ,Young Adult - Abstract
Background Since 2011 Italy has faced an extraordinary increase in migrants arrivals, mainly from the Mediterranean route, one of the world’s most dangerous journeys. The purpose of the present article is to provide a comprehensive picture of the migrants' health status in the "T. Fenoglio" centre, Settimo Torinese (Turin, Italy). Methods A retrospective cross-sectional study was conducted using data collected from June 2016 to May 2018 on adult migrants (over 18 years old) from Africa, Middle East and South East Asia (Bangladesh, Cambodia, India, Nepal). Data was collected through the migrants' medical records. Descriptive statistics were performed on socio-demographic variables. The diagnosed diseases were anonymously registered and classified according to the International Classification of Primary Care (ICPC-2). Conditional Inference Trees were used to perform a descriptive analysis of the sample and to detect the covariates with the strongest association with the variables Disease on arrival, Disease after arrival, ICPC on arrival and ICPC after arrival. Results Analyzed observations were 9 857. 81.8% were men, median age was 23 (Interquartile range: 20.0–27.4). 70.3% of the sample came from Sub-Saharan Africa. 2 365 individuals (24%) arrived at the centre with at least one disease. On arrival, skin (27.71%), respiratory (14.46%), digestive (14.73%) and generic diseases (20.88%) were the most frequent. During the stay respiratory diseases were the most common (25.70%). The highest probability of arriving with a disease occurred in 2018 and during the period September–November 2016, in particular for people from the Horn of Africa. During this period and also in the first half of 2017, skin diseases were the most reported. In seasons with lower prevalence of diseases on arrival the most common disease code was generic for both men and women (usually fever or trauma). Conclusions This study provides information on the diverse diseases that affect the asylum seekers population. In our sample, the Horn of Africa was the most troubled area of arrival, with severe conditions frequently reported regarding skin diseases, in particular scabies. 2018 was the most critical year, especially for migrants from the Horn of Africa and Sub-Saharan Africa. During the stay at the camp, the prevalence of respiratory diseases increased. However, skin diseases remained the main issue for people from the Horn of Africa. Overall, the most reported diseases in the sample were dermatological, respiratory, digestive and generic diseases, both on arrival and during the stay. A better understanding of the health status of asylum seekers is an important factor to determine a more efficient reception and integration process and a better allocation of economic resources in the context of migrants' health care.
- Published
- 2022
47. A blood DNA methylation biomarker for predicting short-term risk of cardiovascular events
- Author
-
Andrea Cappozzo, Cathal McCrory, Oliver Robinson, Anna Freni Sterrantino, Carlotta Sacerdote, Vittorio Krogh, Salvatore Panico, Rosario Tumino, Licia Iacoviello, Fulvio Ricceri, Sabina Sieri, Paolo Chiodini, Rose Anne Kenny, Aisling O’Halloran, Silvia Polidoro, Giuliana Solinas, Paolo Vineis, Francesca Ieva, and Giovanni Fiorito
- Abstract
Background: Recent evidence highlights the epidemiological value of blood DNA methylation (DNAm) as surrogate biomarker for exposures to risk factors for non-communicable diseases (NCD). DNAm surrogate of exposures predict diseases and longevity better than self-reported or measured exposures in many cases. Consequently, disease prediction models based on blood DNAm surrogates may outperform current state-of-art prediction models. This study aims to develop novel DNAm surrogates for cardiovascular diseases (CVD) risk factors and develop a composite biomarker predictive of CVD risk. We compared the prediction performance of our newly developed risk score with the state-of-art DNAm risk scores for cardiovascular diseases, the ‘next-generation’ epigenetic clock DNAmGrimAge, and the prediction model based on traditional risk factors SCORE2.Results: Using data from the EPIC Italy cohort, we derived novel DNAm surrogates for BMI, blood pressure, fasting glucose and insulin, cholesterol, triglycerides, and coagulation biomarkers. We validated them in four independent datasets from Europe and the US. Further, we derived a DNAmCVDscore predictive of the time-to-CVD event as a combination of several DNAm surrogates. ROC curve analyses show that DNAmCVDscore outperforms previously developed DNAm scores for CVD risk and SCORE2 for short-term CVD risk. Interestingly, the performance of DNAmGrimAge and DNAmCVDscore was comparable (slightly lower for DNAmGrimAge, although the differences were not statistically significant).Conclusions: We described novel DNAm surrogates for CVD risk factors useful for future molecular epidemiology research, and we described a blood DNAm-based composite biomarker, DNAmCVDscore, predictive of short-term cardiovascular events. Our results highlight the usefulness of DNAm surrogate biomarkers of risk factors in epigenetic epidemiology to identify high-risk populations. In addition, we provide further evidence on the effectiveness of prediction models based on DNAm surrogates and discuss methodological aspects for further improvements. Finally, our results encourage testing this approach for other NCD diseases by training and developing DNAm surrogates for disease-specific risk factors and exposures.
- Published
- 2022
48. Cruciferous Vegetable Intake and Bulky DNA Damage within Non-Smokers and Former Smokers in the Gen-Air Study (EPIC Cohort)
- Author
-
Marco Peluso, Armelle Munnia, Valentina Russo, Andrea Galli, Valeria Pala, Yvonne T. van der Schouw, Matthias B. Schulze, Elisabete Weiderpass, Rosario Tumino, Calogero Saieva, Amiano Exezarreta Pilar, Dagfinn Aune, Alicia K. Heath, Elom Aglago, Antonio Agudo, Salvatore Panico, Kristina Elin Nielsen Petersen, Anne Tjønneland, Lluís Cirera, Miguel Rodriguez-Barranco, Verena Katzke, Rudolf Kaaks, Fulvio Ricceri, Lorenzo Milani, Paolo Vineis, and Carlotta Sacerdote
- Subjects
Dietary Fiber ,ADN ,4-AMINOBIPHENYL-HEMOGLOBIN ADDUCTS ,cruciferous vegetables ,bulky oxidative lesions ,COLORECTAL-CANCER ,Clinical trials ,Neoplasms ,P-32-POSTLABELING DETECTION ,Vegetables ,Humans ,Prospective Studies ,Nutrició ,Hortalisses ,Nutrition ,Science & Technology ,Nutrition and Dietetics ,Smokers ,Nutrition & Dietetics ,EPIC ,diet ,DNA damage ,B(a)P-adducts ,Smoking ,DNA ,Non-Smokers ,ADDUCT LEVELS ,Diet ,Brassicaceae ,NUTRITION ,1111 Nutrition and Dietetics ,WESTERN LIGURIA ,Life Sciences & Biomedicine ,LUNG-CANCER RISK ,0908 Food Sciences ,Assaigs clínics ,APIACEOUS VEGETABLES ,Food Science ,DNA Damage - Abstract
Epidemiologic studies have indicated that cruciferous vegetables can influence the cancer risk; therefore, we examined with a cross-sectional approach the correlation between the frequent consumption of the total cruciferous vegetables and the formation of bulky DNA damage, a biomarker of carcinogen exposure and cancer risk, in the Gen-Air study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. DNA damage measurements were performed in the peripheral blood of 696 of those apparently healthy without cancer controls, including 379 never-smokers and 317 former smokers from seven European countries by the 32P-postlabeling assay. In the Gen-Air controls, the median intake of cruciferous vegetables was 6.16 (IQR 1.16–13.66) g/day, ranging from 0.37 (IQR 0–6.00) g/day in Spain to 11.34 (IQR 6.02–16.07) g/day in the UK. Based on this information, participants were grouped into: (a) high consumers (>20 g/day), (b) medium consumers (3–20 g/day) and (c) low consumers (
- Published
- 2022
49. Multimorbidity and SARS-CoV-2–Related Outcomes: Analysis of a Cohort of Italian Patients
- Author
-
Alberto Catalano, Lucia Dansero, Winston Gilcrease, Alessandra Macciotta, Carlo Saugo, Luca Manfredi, Roberto Gnavi, Elena Strippoli, Nicolás Zengarini, Valeria Caramello, Giuseppe Costa, Carlotta Sacerdote, and Fulvio Ricceri
- Subjects
Public Health, Environmental and Occupational Health ,Health Informatics - Abstract
Background Since the outbreak of the COVID-19 pandemic, identifying the main risk factors has been imperative to properly manage the public health challenges that the pandemic exposes, such as organizing effective vaccination campaigns. In addition to gender and age, multimorbidity seems to be 1 of the predisposing factors coming out of many studies investigating the possible causes of increased susceptibility to SARS-CoV-2 infection and adverse outcomes. However, only a few studies conducted have used large samples. Objective The objective is to evaluate the association between multimorbidity, the probability to be tested, susceptibility, and the severity of SARS-CoV-2 infection in the Piedmont population (Northern Italy, about 4 million inhabitants). For this purpose, we considered 5 main outcomes: access to the swab, positivity to SARS-CoV-2, hospitalization, intensive care unit (ICU) admission, and death within 30 days from the first positive swab. Methods Data were obtained from different Piedmont health administrative databases. Subjects aged from 45 to 74 years and infections diagnosed from February to May 2020 were considered. Multimorbidity was defined both with the Charlson Comorbidity Index (CCI) and by identifying patients with previous comorbidities, such as diabetes and oncological, cardiovascular, and respiratory diseases. Multivariable logistic regression models (adjusted for age and month of infection and stratified by gender) were performed for each outcome. Analyses were also conducted by separating 2 age groups (45-59 and 60-74 years). Results Of 1,918,549 subjects, 85,348 (4.4%) performed at least 1 swab, of whom 12,793 (14.9%) tested positive for SARS-CoV-2. Of these 12,793 subjects, 4644 (36.3%) were hospitalized, 1508 (11.8%) were admitted to the ICU, and 749 (5.9%) died within 30 days from the first positive swab. Individuals with a higher CCI had a higher probability of being swabbed but a lower probability of testing positive. We observed the same results when analyzing subjects with previous oncological and cardiovascular diseases. Moreover, especially in the youngest group, we identified a greater risk of being hospitalized and dying. Among comorbidities considered in the study, respiratory diseases seemed to be the most likely to increase the risk of having a positive swab and worse disease outcomes. Conclusions Our study shows that patients with multimorbidity, although swabbed more frequently, are less likely to get infected with SARS-CoV-2, probably due to greater attention on protective methods. Moreover, a history of respiratory diseases is a risk factor for a worse prognosis of COVID-19. Nonetheless, whatever comorbidities affect the patients, a strong dose-response effect was observed between an increased CCI score and COVID-19 hospitalization, ICU admission, and death. These results are important in terms of public health because they help in identifying a group of subjects who are more prone to worse SARS-CoV-2 outcomes. This information is important for promoting targeted prevention and developing policies for the prioritization of public health interventions.
- Published
- 2023
50. Biomarkers of the transsulfuration pathway and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC) study
- Author
-
Joanna L. Clasen, Alicia K. Heath, Heleen Van Puyvelde, Inge Huybrechts, Jin Young Park, Pietro Ferrari, Ghislaine Scelo, Arve Ulvik, Øivind Midttun, Per Magne Ueland, Kim Overvad, Anne Kirstine Eriksen, Anne Tjønneland, Rudolf Kaaks, Verena Katzke, Matthias B. Schulze, Domenico Palli, Claudia Agnoli, Paolo Chiodini, Rosario Tumino, Carlotta Sacerdote, Raul Zamora‐Ros, Miguel Rodriguez‐Barranco, Carmen Santiuste, Eva Ardanaz, Pilar Amiano, Julie A. Schmidt, Elisabete Weiderpass, Marc Gunter, Elio Riboli, Amanda J. Cross, Mattias Johansson, David C. Muller, Clasen, J. L., Heath, A. K., Van Puyvelde, H., Huybrechts, I., Park, J. Y., Ferrari, P., Scelo, G., Ulvik, A., Midttun, O., Ueland, P. M., Overvad, K., Eriksen, A. K., Tjonneland, A., Kaaks, R., Katzke, V., Schulze, M. B., Palli, D., Agnoli, C., Chiodini, P., Tumino, R., Sacerdote, C., Zamora-Ros, R., Rodriguez-Barranco, M., Santiuste, C., Ardanaz, E., Amiano, P., Schmidt, J. A., Weiderpass, E., Gunter, M., Riboli, E., Cross, A. J., Johansson, M., Muller, D. C., and Cancer Research UK
- Subjects
Cancer Research ,dietary biomarkers ,transsulfuration ,dietary biomarker ,HOMOCYSTEINE ,METABOLISM ,urologic and male genital diseases ,vitamin B6 ,SERUM ,INFLAMMATION ,Humans ,1112 Oncology and Carcinogenesis ,ASSAY ,AMINO-ACIDS ,Oncology & Carcinogenesis ,Cysteine ,Prospective Studies ,Carcinoma, Renal Cell ,Homocysteine ,Carcinoma, Renal Cell/epidemiology ,Science & Technology ,Kidney Neoplasms/epidemiology ,PLASMA ,kidney cancer ,Bayes Theorem ,Kidney Neoplasms ,Vitamin B 6 ,Oncology ,VITAMIN-B-12 ,Case-Control Studies ,Pyridoxal Phosphate ,CYSTEINE ,Life Sciences & Biomedicine ,Biomarkers ,FOLATE - Abstract
Previous studies have suggested that components of one-carbon metabolism, particularly circulating vitamin B6, have an etiological role in renal cell carcinoma (RCC). Vitamin B6 is a cofactor in the transsulfuration pathway. We sought to holistically investigate the role of the transsulfuration pathway in RCC risk. We conducted a nested case-control study (455 RCC cases and 455 matched controls) within the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Plasma samples from the baseline visit were analyzed for metabolites of the transsulfuration pathway, including pyridoxal 5'-phosphate (PLP, the biologically active form of vitamin B6), homocysteine, serine, cystathionine, and cysteine, in addition to folate. Bayesian conditional logistic regression was used to estimate associations of metabolites with RCC risk as well as interactions with established RCC risk factors. Circulating PLP and cysteine were inversely associated with RCC risk, and these associations were not attenuated after adjustment for other transsulfuration metabolites (odds ratio (OR) and 90% credible interval (CrI) per 1 SD increase in log concentration: 0.76 [0.66, 0.87]; 0.81 [0.66, 0.96], respectively). A comparison of joint metabolite profiles suggested substantially greater RCC risk for the profile representative of low overall transsulfuration function compared to high function (OR 2.70 [90% CrI 1.26, 5.70]). We found some statistical evidence of interactions of cysteine with body mass index, and PLP and homocysteine with smoking status, on their associations with RCC risk. In conclusion, we found evidence suggesting that the transsulfuration pathway may play a role in metabolic dysregulation leading to RCC development. ispartof: INTERNATIONAL JOURNAL OF CANCER vol:151 issue:5 pages:708-716 ispartof: location:United States status: published
- Published
- 2022
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.